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Abstract 
Glioblastomas are the most aggressive and most common type of primary brain neoplasms 
and are associated with poor prognosis despite advances in surgical and oncological 
treatments.  Currently available treatments include surgical resection, fractionated external 
beam radiotherapy and chemotherapy.  This study aimed to investigate markers of cell 
division cycle, apoptosis and autophagy flux in an attempt to identify biomarkers with 
prognostic and/or predictive significance.   
The cell cycle markers studied included: Mcm2, expressed throughout the cell cycle; Cyclin 
A, an S-phase cyclin; Geminin, a protein that prevents re-initiation; and Phosphohistone H3 
(PHH3), a marker of mitosis.  Apoptotic markers included two anti-apoptotic proteins, Bcl-2 
and Bcl-xl; a pro-apoptotic protein, Bak; and a final executioner caspase, caspase 3.  
Markers of autophagy flux included LC3B, a ubiquitin like protein that form part of the core 
autophagy machinery; and p62, a mammalian autophagy receptor that binds ubiquitinated 
proteins. 
A total of 66 patients were recruited to the study between 2007 and 2009.  Data were 
collected on patient demographics, pre-operative Karnofsky score, surgical and adjuvant 
treatment and survival.  A tissue micro-array, constructed using glioblastoma tissue was 
immunohistochemically-stained using antibodies against a panel of markers against the 
molecules described above.  A semiquantitative labelling index (LI) was calculated for cell 
cycle and apoptotic markers using an average of 18 high power fields (hpf) in three replicate 
cores.  Staining scores were calculated for markers of autophagy flux on the basis of 
cytoplasmic staining intensity (1-3) and percentage of cells with nuclear staining (1<50%, 
2>50%).  
Cell cycle marker LI were calculated from a cohort of 66 patients, who were further 
subdivided into two groups: Group 1 (n=50) underwent surgery and radiotherapy with 24 
patients receiving temozolomide; and Group 2 (n=16) received surgical treatment only.  In 
group 1, a LI, higher than the median value for Geminin and Cyclin A correlated with 
prolonged survival when tumours received adjuvant treatment (Kaplan Meier test, p=0.0046 
and p =0.0063 respectively).  In group 1, Mcm2 and PHH3 LI did not correlate significantly 
with survival.  There was no relationship between patient survival and LI for any marker in 
group 2.  A reduction in the LI of Mcm2, Geminin and Cyclin A was observed following 
administration of adjuvant treatment in three patients with recurrent glioblastoma. 
Apoptotic marker LI were calculated in 28 patients, due to limited tissue availability; values 
below the median for Bak expression conferred a survival advantage in these patients by 
Kaplan Meier analysis (p = 0.0039).   
LC3b and p62 staining scores were calculated in 45 patients and correlated significantly 
with each other.  Whilst no significant correlation was observed between LC3b staining 
score and patient survival, p62 staining above the median conferred a survival disadvantage 
(Kaplan Meier analysis, p =0.017).   
Geminin and Cyclin A, each showed potential as independent prognostic markers in 
glioblastomas receiving adjuvant treatment.  This may reflect the fact that geminin and 
cyclin A both estimate proliferating cell sub-populations sensitive to 
radiotherapy/chemotherapy.  The addition of these markers could therefore contribute 
valuable prognostic information if added to the glioblastoma diagnostic panel.  The 
association of high Bak expression with survival advantage suggests a possible, as yet 
unknown, role of this pro-apoptotic protein in glioblastoma oncogenesis.  The association of 
high p62 expression with decreased survival confirms the important role of autophagy flux 
in glioblastoma resistance to treatment and suggests a target for future research and targeted 
therapy. 
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1:1) Glioblastoma: Background and challenges 
Primary brain tumours account for approximately 2% of all primary tumours.  Glioblastomas 
are the most aggressive and most common type of primary brain neoplasms (figure 1.1) 
representing 12-15% of all primary intracranial neoplasms with an annual incidence of 3-
4/100000 population per year (Louis et al., 2007).  Although they can present at any age the 
peak incidence is between 45 and 75 years of age with a slight male preponderance. 
The presentation of patients with glioblastoma can be highly variable and depends on the 
location and size of the tumour.  Symptoms can occur secondary to raised intracranial 
pressure (headaches, nausea, vomiting), focal mass effect (hemiparesis, aphasia/dysphasia, 
hemiparesis, sensory symptoms, visual disturbance), mood and personality changes or 
seizures (Preusser et al., 2011).   
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Figure 1.1: Relative frequencies of gliomas.  Adapted from Preusser et al., 2011) 
 
Primarily on the basis of their clinical presentation, glioblastomas are classified as primary or 
secondary.  This distinction between primary and secondary glioblastomas was first described 
in 1940 by a german neuropathologist, Hans-Joachim Scherer (Peiffer and Kleihues, 1999).  
Primary glioblastomas represent the vast majority (more than 90%) of glioblastomas, usually 
in older patients, and these have a relatively short clinical presentation (Ohgaki and Kleihues, 
2007); occuring without clinical or histopathological evidence of pre-existing less malignant 
precursor lesion. Secondary glioblastomas develop through progressive transformation from 
diffuse astrocytoma (WHO Grade II) or anaplastic astrocytoma (WHO Grade III) (Ohgaki et 
al., 2004; Ohgaki and Kleihues, 2007).  Secondary glioblastomas are less frequent (less than 
10% of all glioblastomas) and tend to occur in younger patients (Ohgaki et al., 2004; Ohgaki 
and Kleihues, 2005).  Approximately 70% of diffuse astrocytomas will progress to 
Glioblastoma 
51.4% 
Oligodendroglial 
tumours (II, III) 
13.6% 
Ependymoma (II, 
III) 8.5% 
Other gliomas (I, II, 
III) 4.1% 
Pilocytic 
astrocytoma (I, II) 
6.5% 
Diffuse 
astrocytoma (II, III) 
15.9% 
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glioblastoma over an interval which varies from 1-10 years with a mean period of 4-5 years 
(Ohgaki and Kleihues, 2007).  Primary and secondary glioblastomas are clinically and 
morphologically indistinguishable and when adjusted for patient age, carry a similar 
prognosis (Ohgaki et al., 2004; Ohgaki and Kleihues, 2005).   Ohgaki and Kleihues have 
described the genetic alterations that occur during the evolution of primary and secondary 
glioblastoma (Ohgaki and Kleihues, 2007); these are summarized in figure 1.2  More recently 
Nobusawa et al. (2009) have described IDH1 mutations in primary and secondary 
glioblastoma.  In their study, IDH1 mutation was found in 3.7% of primary glioblastomas 
whereas 73% of secondary glioblastomas exhibited IDH1 mutation.  Nobusawa et al. further 
reported that IDH1 mutation as a genetic marker of secondary glioblastoma corresponded to 
respective clinical diagnosis in 95% of the cases (Nobusawa et al., 2009).     
 
Figure 1.2:  Genetic pathways to primary and secondary glioblastomas at the 
population level (Ohgaki and Kleihues, 2007).   
 
Histologically, glioblastoma is characterized by poorly differentiated astrocytic tumour cells 
exhibiting nuclear atypia, cellular pleomorphism and brisk mitotic activity. The tumours are 
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also associated with vascular thrombosis, microvascular proliferation and necrosis (Louis et 
al., 2007).  While most glioblastomas are unilateral occupying much of the lobe, those 
located in corpus callosum and brain stem can be bilaterally symmetrical.  They are also 
characterized by rapid spread through neighbouring structures particularly the corpus 
callosum, fornix, internal capsule, anterior commissure and optic radiations (Louis et al., 
2007).   Another clinically important feature is the location of invading cells outside the 
contrast-enhancing rim of the tumour as seen on cranial imaging (Figure 1.3a and 1.3b). This 
allows these cells to escape surgical resection and evade the higher doses of radiation during 
radiotherapy (Louis et al., 2007).  This feature has implications in term of future local 
recurrence and hence poor outcome.  
 
1.3a 1.3b 
Figures 1.3a and 1.3b: Axial T1 Gadolinium enhanced (figure 2a) and axial FLAIR 
(figure 2b) MRI images demonstrating a  right parietal glioblastoma (confirmed on 
histology).  The tumour demonstrates characteristic peripheral contrast enhancment with 
Gadolinium (Figure 2a).  Note the extension of FLAIR signal beyond the contrast 
enhancing tumour margins in figure 2b suggesting the presence of invading tumour cells.   
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Histologically up to 2.4% of all glioblastomas are truly multifocal (Batzdorf and Malamud, 
1963; Russel and Rubinstein, 1989).  Distinct histological subtypes of Glioblastoma are 
recognized and described (Louis et al., 2007).  These include Giant cell glioblastoma, 
Gliosarcoma and Glioblastoma with oligodendroglial components.   
Giant cell glioblastoma accounts for up to 5% of glioblastoma (Homma et al., 2006) and is 
histologically characterized by predominance of multinucleated giant cells with an abundant 
stromal reticulin network.  Giant cell glioblastomas carry a relatively poor prognosis (Huang 
et al., 1996) although some studies (Shinojima et al., 2004) suggest a better outcome in 
comparison to usual glioblastoma, possibly due to less infiltrative nature.   
Gliosarcoma is a histological variant of glioblastoma characterized by glial and mesenchymal 
differentiation conferring a biphasic tissue pattern.  It comprises of 2% of all glioblastomas 
and has been suggested to carry a favourable prognosis as compared to the usual 
glioblastomas (Maiuri et al., 1990).   
Glioblastoma with oligodendroglial component has been recognized as a distinct entity in 
WHO classification 2007.  As the name suggests, these tumours exhibit foci resembling 
oligodendrogliomas and have been suggested to carry a better prognosis as compared to 
standard glioblastoma (Kraus et al., 2001), possibly due to relative chemosensitivity of the 
oligodendroglial component.   
Glioblastoma is associated with a poor prognosis as compared to other common malignancies 
including prostate, breast, lung and colon cancer and has a median survival of approximately 
12 months, despite recent advances in surgical and oncological interventions (Westermark, 
2012).  Currently available treatment options include surgical resection (where feasible), 
fractionated focal external beam radiotherapy and chemotherapy.   
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Gross total resection (GTR), where feasible, remains the first and most important step in 
treatment of glioblastoma (Mineo et al., 2007; Filipini et al., 2008; Gorlia et al., 2008) and 
has been shown to enhance patient survival (Stummer et al., 2008; McGirt et al., 2008; Sanai 
and Berger, 2008; McGirt et al., 2009; Dea et al., 2012).  Surgery provides a cytoreductive 
treatment, helps to alleviate tumour mass effect, reduces intracranial pressure and contributes 
to increase the efficacy of oncological treatments.  Blurring of margin between tumour tissue 
and healthy brain in the infiltration zone and the presence of tumour cells beyond the contrast 
enhancing tumour margin make the achievement of GTR very challenging.  At the same time, 
the advantages associated with attempts at GTR have to be balanced with the risk of causing 
neurological deficits especially when the tumour is located close to or in an eloquent location.  
Recent advances in preoperative and intraoperative advanced MRI imaging (Gonzalez-
Darder, 2010), use of high resolution intraoperative ultrasonography, 5-Aminolevulinic acid 
aided tumour resection (Stummer et al., 2006; Feigl et al., 2010) and intraoperative 
neurophysiological monitoring (Feigl et al., 2010) have all helped to achieve GTR 
particularly when the tumour is located in eloquent areas.  
Before the widespread clinical use of temozolomide chemotherapy for glioblastoma over the 
past 7 years, radiotherapy following surgery was the only available treatment.  The addition 
of radiotherapy following surgery improves survival as compared with radiotherapy alone 
having been demonstrated to improve patient survival from 3-4 months to 7-12 months 
(Stupp et al., 2005).  Currently, radiotherapy with concomitant and adjuvant temozolomide is 
the mainstay of oncological treatment for glioblastoma and has been demonstrated to enhance 
median patient survival by more than two months when compared with radiotherapy alone 
(Stupp et al., 2005; Stupp et al., 2009).  Temozolomide is an oral alkylating agent with good 
penetration across the blood brain barrier and causes DNA damage by generating methylation 
at N-7 or O-6 position of guanine residues.   Some tumour cells are able to repair this 
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methylation by expressing an enzyme O-6-methylguanine-DNA methyltransferase (MGMT).  
Epigenetic silencing of MGMT by promoter methylation compromises tumour cells’ ability 
to repair DNA and increases their susceptibility to temozolomide.  MGMT promoter 
methylation can occur in approximately 45% of glioblastomas and has been shown to confer 
a survival advantage when treated with radiotherapy and temozolomide (Hegi et al., 2005).   
In addition to Temozolomide, surgically implanted BCNU (Carmustine) polymer wafers 
(Gliadel) have been approved by NICE and have been shown to improve patient survival in 
Glioblastoma (Westphal et al., 2006; Dixit et al., 2011; Barr and Grundy, 2012).  Recently a 
few retrospective and prospective trials (Lechapt-Zalcman et al., 2012; Noel G et al., 2012; 
Bock HC et al., 2010; McGirt MJ et al., 2009) have reported the safety and efficacy of the 
use of BCNU at the time of primary surgery followed by radiotherapy with concomitant and 
adjuvant temozolomide.  Most of these trials have reported no significant increase in serious 
toxicity and an incremental gain of 2-3 months in median survival in comparison with 
published results using carmustine wafers or concomitant and adjuvant temozolomide alone 
(Dixit et al., 2011).  However, these studies have small numbers of patients and in the 
absence of any phase III trials, the sequential use of carmustine wafers followed by 
radiotherapy with concomitant and adjuvant temozolomide is currently not the standard of 
care in the treatment of glioblastoma.    
Apart from temozolomide and BCNU, other anti-neoplastic agents have been used in the 
treatment of glioblastoma but with limited success at best. PCV chemotherapy is a 
combination chemotherapy of Procarbazine, Lomustine (CCNU) and Vincristine and has 
been used extensively for the treatment of glioblastoma for over 30 years (Levin and Wilson, 
1976).  A Medical Research Council randomized control trial involving 674 patients with 
grade 3 and grade 4 astrocytomas (67% with histologically confirmed glioblastoma) showed 
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no significant survival benefit with PCV chemotherapy after radiotherapy versus radiotherapy 
alone (MRC brain tumour working party, 2000).  Kappelle et al. (2001) have reported the 
results of PCV chemotherapy in 63 patients with recurrent glioblastoma.  In this study, PCV 
chemotherapy resulted in complete response in 3%, partial response in 8%, stable disease in 
25% of the patients and progression free survival at 6 months in 29%.  Schmidt F et al. 
(2006) however reported only 3 partial responses in 86 patients with recurrent glioblastoma 
and progression-free survival at 6 months in 38.4%.  More recently Brada M et al. (2010) 
have reported a prospective randomized trial comparing the results of temozolomide (in two 
different dose regimens) versus PCV chemotherapy in 447 chemotherapy-naive patients with 
recurrent high grade glioma.  Brada M et al. did not show any clear benefit of temozolomide 
over PCV chemotherapy.  Currently PCV chemotherapy is mostly used as a second line 
chemotherapy agent in recurrent glioblastoma.   
In summary, patient age, Karnofsky performance score, tumour location, gross total 
resection, radiotherapy, temozolomide, MGMT status are factors known to influence 
outcome in glioblastoma (Lamborn et al., 2004; Mineo et al., 2007).  The overall prognosis 
however continues to remain poor with most patients dead within 15 months of diagnosis 
(Westermark, 2012).     
The focus of this thesis is to study markers of cellular proliferation, survival and cell death in 
glioblastomas and to identify specific biological markers which could be used on paraffin-
embedded surgical biopsy specimens in an effort to predict the likely response of individual 
tumours to adjuvant treatment and thus aid in clinical decision making and better targeting of 
currently available treatments. 
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1:2) Cell division cycle 
The cell division cycle is a series of exquisitely controlled processes leading to cell 
reproduction (Murray and Hunt, 1993; Nasmyth, 1996; Stillman, 1996; Csikasz-Nagy A, et 
al. 2006; Budirahardja and Gonczy, 2009; Uhlmann et al., 2011). The timing and 
coordination of these events is controlled by a complex regulatory network to ensure that cell 
division is accomplished without the introduction of deleterious mutations, chromosomal 
abnormalities and unequal distribution of chromatin between daughter cells (Bell and Dutta, 
2002; Coverley and Laskey, 1994; Sun and Kong, 2010; Uhlmann et al. 2011).  Defective 
cell cycle arrest at the respective checkpoints is associated with genomic instability and 
oncogenesis (Loeb, 1991; Bartek and Lucas, 2001; Nyberg et al., 2002; Aguilera and Gomez-
Gonzales, 2008; Langerak aand Russell, 2011). 
1:3) Cell cycle: phases  
Cells in active state of proliferation are said to be in cell cycle.  The cell cycle has four 
distinct phases namely G1, S, G2 and M.  G1 and G2 are gap phases which prepare the cell 
for the next phase and precede S and M phases respectively.  Chromosomal duplication 
occurs in the S (for synthesis) phase and chromosomal segregation occurs in the M (for 
Mitosis) phase (Murray and Hunt, 1993; Morgan, 2007).   
Following the cell division cycle, the cell either enters a quiescent or specialized resting 
phase called G0 or re-enters the cell cycle.  Most cells in terminally differentiated tissues are 
in G0 phase and re-enter the cell cycle upon appropriate stimulation including cellular injury 
and growth factors.     
The M phase has four distinct phases namely prophase, metaphase, anaphase and telophase.  
DNA chromosomes condense and the mitotic spindle is assembled in prophase.  The 
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chromosomes align upon the spindle in metaphase.  The chromosomes then segregate by 
releasing cohesion and reel in the spindle (anaphase) until they decondense and form nuclei 
(telophase).  Together G1, S and G2 phases are also called interphase (Morgan, 2007).   
Progression through the cell cycle follows an organized pattern to ensure that DNA 
replication occurs once and only once through the cell cycle and precedes chromosomal 
segregation which in turn precedes cytokinesis.  Throughout the cell cycle, inbuilt 
mechanisms in the form of checkpoints ensure that the genetic information is transferred 
completely and correctly to the daughter cells (Murray and Hunt, 1993; Morgan 2007) (figure 
1.3).  Detection of irreparable genetic damage at these checkpoints results in activation of 
apoptosis or programmed cell death.  Cells lacking effective checkpoints display genomic 
instability, faulty DNA replication or aberrant segregation (Loeb, 1991).   
 
Figure 1.4:  Sites of important cell cycle checkpoints in mammalian cell cycle.   
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1:4) Cyclins, CDKs and CDKIs 
Progression through the cell cycle is controlled by the synthesis, degradation and state of 
phosphorylation of proteins called cyclins (Evans et al., 1983).  The cyclins form complexes 
with Cyclin dependent kinases (CDKs) and these cyclin-CDK complexes then control 
progression through the cell cycle by activating a variety of proteins by phosphorylation 
(Budirahardja and Gonczy, 2009).  The cyclin-CDK complexes are the core controlling 
mechanism that drives the eukaryotic cell cycle (Budirahardja and Gonczy, 2009).  The 
cyclins display periodic oscillatory changes in concentration during different phases of the 
cell cycle and this helps to generate CDK activity that forms the foundation of the cell cycle 
control system cells and also ensures a unidirectional cell cycle progression (Budirahardja 
and Gonczy, 2009; Morgan, 1997; Nurse, 1990).  CDK regulation is achieved by association 
with cyclins and inhibitor proteins, phosphorylation-dephosphorylation and cyclin synthesis 
or degradation. The cyclins are divided into four classes based on their expression, timing in 
the cell cycle and their function: G1, G1/S, S and M phase cyclins.  The cyclin concentration 
in turn is regulated by cyclin gene expression and destruction of cyclins by proteolysis.  The 
CDK activity is modulated by a variety of cyclin dependent kinase Inhibitors (CDKI).  These 
include p21, p27 and p57 with a broad inhibition activity and p15, p16 and p19 (INK family) 
with specific inhibition of CDK4 and CDK6. 
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Figure1.5:  Cyclin-CDK complexes and their distribution at different phases of the cell cycle.  
Cyclin D1 is expressed in the latter third of G1 and together with cyclins E and A is involved 
in progression through the G1/S transition. Cyclin A is expressed in S and to a variable extent 
into G2. In S-phase, cyclin A is complexed to CDK2, however, in G2 and early M, it is 
complexed to CDK1. Cyclin B1 is expressed in both G2 and prophase of M. In G2, cyclinB1 
is identified as a cytoplasmic molecule, in prophase of M the molecule is found in the 
nucleus until, with breakdown of the nuclear membrane, staining becomes diffuse. 
 
Different models of cell cycle control have been proposed (Chen et al, 2004; Csikasz-Nagy et 
al., 2006).  More recently, Gerard and Goldbeter have proposed an integrated computational 
model for the network of CDKs that control the dynamics of the cell cycle (Gerard and 
Golbeter, 2009 and 2011).  The CDK network consists of four coupled members including 
cyclin D/CDK4-6, cyclin E/CDK2, cylcin A/CDK2 and cyclin B/CDK1 and sequential 
activation of these complexes respectively control progression through G1, transition to DNA 
replication in S, transition to G2 and finally G2/M transition allowing entry into M phase 
(figure 1.4).  The model also includes retinoblastoma gene (pRb) and transcription factor E2F 
which inhibit and promote progression through cell cycle respectively.  Another feature of the 
model is the existence of restriction point beyond which the cell cycle progression continues 
independent of growth factors.   
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1:5) G1 phase and restriction point 
During G1 phase, nucleotide and proteins of the replicative machinery are synthesized and 
the expression of genes associated with deoxynucleotide synthesis are upregulated in 
preparation for DNA synthesis.  G1 cyclin (Cyclin D in vertebrates) helps coordinate cell 
growth with entry into the new cell cycle and together with the G1/S cyclin (Cyclin E) 
triggers progression into a new cell cycle at the restriction point (start point in Yeast).  This 
leads to processes culminating in DNA replication.  The level of cyclin D rises early in G1 
and is limited to late G1 whereas the expression of cyclin E is limited to late G1 and early S 
phase.  Cyclin D forms complexes with Cdk4 or Cdk6 to yield active protein kinase (Hunter 
and Pines, 1994) which phosphorylates Rb which is a key event in G1/S transition (Buschges 
et al. 1999; Hunter and Pines, 1994; Lei et al., 1997; Sawa et al., 1998).  There is also 
increasing evidence to suggest that cyclin D activity is required for activation of cyclin E 
whose complex with CDK2 is required for transition through G1/S checkpoint (Coverley et 
al., 2002).  During early G1 the hypophosphorylated form of pRb binds and inactivates E2F 
transcription factor.  Following phosphorylation of pRb, E2F is released which then 
stimulates transcription of genes required for DNA replication.  In particular E2F leads to 
further expression of cyclin E in a positive feedback loop fashion.    
G1 DNA damage results in a strong and often irreversible block of cell cycle progression at 
restriction point.  The G1 DNA damage response is of two types. The “Rapid” response 
occurring in minutes is mediated by inactivation of Cyclin E-CDK2 causing cell cycle arrest 
in G1 by preventing progression past the restriction point.  p53 activation constitutes the 
“Delayed” or maintenance response.  p53 is a gene regulatory protein that plays a central role 
in cellular response to DNA damage and other stressors, with activation leading to apoptosis 
(Levine., 1997; Harris and Levine, 2005).  It binds directly to the promoters of its target 
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genes and alters the rate at which their transcription in initiated.  In most cases the expression 
of target genes is stimulated and the overall result of p53 is increased production of proteins 
that stimulate cell cycle arrest and promote apoptosis.  At the same time, p53 increases 
transcription of genes encoding apoptosis inhibitors.  In the absence of DNA damage, Mdm2, 
an E3 ubiquitin-protein ligase ubiquitinates p53 thereby promoting its destruction by the 
proteasome.  Upon DNA damage, phosphorylation of Mdm2 and p53 disrupts their 
association, resulting in stabilization and activation of p53.  Phosphorylation of p53 also 
increases its interaction with histone acytylase, p300.  This results in increased acetylation of 
histones and p53, both of which act to increase p53 dependent gene expression.   
1:6) S phase  
During the late M and early G1 phase, a complex of initiator proteins, the Pre-replicative 
complex (Pre-RC), assembles at discrete sites on the chromosome called origins of 
replication (figure 1:5).  Pre-RC is composed of Origin Recognition complex (ORC), Cdt1 
(Chromosomal licencing and DNA replication factor 1), Cdc6 (cell division cycle 6) and the 
Mini-chromosomal protein complex (MCM2-7).  Pre-RC prepares the origins for “licensing” 
(Bell and Dutta, 2002; Coverley and Laskey; 1994, Lei and Tye, 2001).  During the S phase, 
the Pre-RC is transforms into an active Pre-initiation complex by the activity of Cyclin 
E/Cdk2 and Cyclin A/CDK2 complexes.  Once activated, MCM2-7 acts as a DNA helicase 
and unwinds the DNA enabling access to the DNA synthesis machinery (figure 1.5).  Once 
the MCM2-7 complex initiates DNA unwinding and DNA replication commences, re-
replication is prevented by Cyclin A/CDK2 complex which phosphorylates MCM2-7 
rendering it inactive.  Another key factor in preventing re-replication is Geminin, this 
molecule binds to Cdt1, inhibits its association with Cdc6 and prevents reloading of MCM2-7 
complex at the origins (Madine and Laskey, 2001; Wohlschegel et al., 2000; Wohlschlegel et 
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al., 2002).  In mammals, Cyclin A expression is limited to S phase whereas Geminin in 
expressed in S, G2 and M until the anaphase/telophase transition when it is degraded by 
proteolysis mediated by the Anaphase Promoting Complex (APC).  This inactivation then 
releases Cdt1 which is available for the following round of the cell cycle.  These mechanisms 
ensure that Pre-RC reassembly is prevented until the next G1 phase and thus DNA replication 
occurs once and only once during the cell cycle.  
 
 
 
Figure 1.6:  Mcm proteins and licencing of DNA for replication.  In G1 phase, the 
pre-replication complex is assembled which allows Mcm proteins 2-7 to form a 
hexamer at the origins of replication.  Mcm complex acts as a DNA helicase and 
unwinds the DNA.  Cyclin A/Cdk2 then inactivates Mcm complex.  Geminin 
inhibits Cdt1and helps to prevent re-initiation.     
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1:7) G2 and M phases 
During G2, regulatory factors for mitosis are synthesised and modifications occur in the 
chromatin structure to support mitotic chromosomal condensation.  At the onset of mitosis, 
chromosome condensation is mediated by cyclin B/CDK1 Complexes.  Phosphorylation of 
histone H1 by CDK1/cyclin B modifies chromatin structure through alterations in 
nucleosome interactions (Nigg, 1998). CDK1/cyclin B promotes completion of chromosomal 
condensation (Murray and Hunt, 1993) by phosphorylating and consequently activating 
casein kinases and phosphorylating condensins.  In addition it is also thought to stimulate 
centrosome separation and nuclear envelope breakdown and spindle assembly during 
prophase.  The effects of Cyclin B-CDK1 are irreversible once set in motion.  This is due to 
the “all or none” irreversible nature of cyclin B-CDK1 activation (Morgan, 2007).   
At the end of S phase, the cells contain a duplicate set of chromosomes in a tightly associated 
pair called sister chromatids.  During the M phase the sister chromatids are separated and one 
of each pair is distributed to each daughter cell (Nasmyth et al., 2000).   During prophase, the 
chromosomes undergo condensation and the sister chromatid cohesion is loosened by 
removal of DNA catenation and partial loss of cohesion protein that hold the sister 
chromatids together.   
Also in prophase, the centrosome separates, each nucleating its own radial microtubule array 
eventually resulting in the formation of the bipolar microtubule array of mitotic spindle.  
Prometaphase begins when the nuclear envelope breaks down and lasts until the sister 
chromatids are completely attached to the spindle and have migrated to the central spindle.  
Specialised regions of the chromatin called kinetochores form sites by which the sister 
chromatids become attached to the spindle microtubules (Alberts et al., 2002; Murray & 
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Hunt, 1993).  When all the chromosomes are lined up on the mitotic spindle, the cell is said 
to be in metaphase and the structure is referred to as a metaphase plate.   
Cyclin B is the primary M phase cyclin.  Cyclin B/CDK 1 activation begins in G2-phase 
when Wee1 (a nuclear kinase) phosphorylates CDK1.  When phosphorylated at three sites 
(amino acids 14, 15 and around 160) CDK1 is inactive.  However, at the G2/M transition, 
Cdc25 phosphatase dephosphorylates the cyclin B/CDK1 complex (at amino acids 14 and 15 
but not at 160), thus activating it by removing the two phosphate groups from the active site 
of the CDK1 kinase.  Cdc25 is activated by at least two sets of protein kinases.  The first is 
cyclin B/CDK1 forming a positive feedback loop and a second signal is provided by a group 
of kinases, originally described in Drosophila, known as Polo kinases (Nigg, 1998).   
Cyclin A-CDK1 and Cyclin B-CDK1 complexes trigger entry into M phase. Early in mitosis 
Cyclin B-CDK1 stimulates centrosome separation and chromosomal condensation. Later 
Cyclin B-CDK1 controls progression in mitosis by phosphorylation of proteins that control 
spindle assembly and phosphorylation of lamins results in breakdown of the nuclear envelope 
at the end of prophase and events leading to assembly of sister chromatids on the spindle.  
Both cyclin A/CDK1 and cyclin B/CDK1 promote microtubule formation from centrosomes 
(Alberts et al., 2002; Murray & Hunt, 1993; Nigg 1998).  Also Cyclin B-CDK 1 complex 
activates Anaphase Promoting Complex (APC) which acts as a ubiquitin-protein ligase.  APC 
causes destruction of securin, a protein that binds the sister chromatids together (figure 1.6).  
This event is mediated by the APC induced proteolysis of the protein securin.  Securin binds 
to and inactivates a protein known as separase.  Destruction of securin allows activation of 
separase, which is then free to cleave one of the subunits of the cohesin complex, thus 
allowing the sister chromatids to separate (Nasmyth et al., 2000; Morgan, 2007). Fully active 
APC appears to require activation by Cdc20, active cyclin B/CDK1, and completion of 
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correct metaphase alignment of chromatid pairs, although other, as yet unknown, factors may 
be important.  Importantly, APC also promotes the destruction of Cyclin B thereby acting as 
a negative feedback loop for Cyclin B-CDK1 activity (figure 1.7).   
As described above, Cyclin B/CDK1 complex is inactivated upon Cyclin B destruction by 
APC during metaphase.  There are at least two checkpoints during mitosis.  G2/M checkpoint 
controls mitotic entry.  Damaged DNA or stalled DNA replication fork sends inhibitory 
signals that block mitotic entry by preventing activation of CDK1.     
 
 
 
Figure 1.7:  Regulation of sister chromatid separation by APC.   APC mediates 
proteolysis of securin liberating seperase which in turn cleaves cohesion resulting in 
sister chromatid separation.  APC-Cdc20 also mediates the degradation of Cyclin B 
which in turn activates Seperase.   
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Thus, early in prophase, progression into mitosis is tightly regulated by the integrity and 
replication status of the DNA and the activity of the Cdk1/cyclin B complex.  The second 
checkpoint within mitosis is at the metaphase to anaphase transition and involves the APC.  If 
sister chromatids are not attached to the spindle correctly, kinetochores send out inhibitory 
signals to the APC thereby preventing further progression of mitosis until correct spindle 
attachment has been achieved.  Failure of these checkpoints may lead to mis-segregation of 
chromosomes with subsequent generation of daughter cells with chromosomal abnormalities 
and aneuploidy (Kaplan et al., 2001; Shichiri et al., 2002). 
1:8) Markers of cell division cycle and their role in Cancer 
Cancer is a heterogenous group of disease processes characterized by accumulation of genetic 
lesions which translate into increased activity of genes that drive cellular proliferation and 
reduced activity of genes that normally inhibit it.  Markers of the cell division cycle can be 
used to estimate tumour cell populations in different phases of the cell cycle and this, in turn, 
may be important in predicting response to treatment because of varying sensitivity of cells in 
different phases of the cell cycle to adjuvant treatment (Terasima et al., 1963; Hama et al., 
2003; Gravina et al., 2010) (figure 1.7).   
Cells are most radiosensitive in G2 and M phase of the cell cycle.  Cells in G1 are relatively 
resistant to radiotherapy whereas cells in S phase are the most radioresistant (Quitet et al., 
1991; Tell et al., 1998).  Quitet et al. investigated two squamous cell lines and found the 
radioresistant cell line to contain twice the number of cells in S-phase in comparison with the 
radiosensitive line.  On a similar note, Tell et al. reported that peripheral blood lymphocytes 
from patients with head and neck cancer who are non-responsive to radiotherapy had a higher 
level of cells in the S-phase compared with partial and complete responders.    
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Figure 1.8:  Cell cycle phases and sensitivities to various therapies at different phases 
of the cell cycle.  Debulking surgery results in more of the remaining tumour cells 
entering the cell cycle due to better availability of substrates (oxygen and nutrients).  
Cells are more sensitive to radiotherapy in G2 and M phases.  Chemotherapy agents 
work primarily during S or M phases of the cell cycle.   
 
The markers of cell cycle phase distribution studied in this thesis include minichromosome 
maintenance protein-2 (Mcm-2), cyclin-A, geminin and Phosphorylated Histone H3 (PHH3), 
these markers have previously been used as surrogate markers of cell phase distribution in a 
variety of tumour types.  The expression of these markers in gliomas is discussed separately 
in 1:9. 
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Figure 1.9:  Schematic diagram demonstrating the distribution of Mcm2, Cyclin 
A, Geminin and PHH3 in the cell division cycle.  
 
Mcm-2 is a 100kDa nuclear protein that is part of a multimeric heterohexamer complex 
comprising Mcm proteins 2-7 (Lei and Tye, 2001; Madine and Laskey, 2001; Kearsey and 
Labib, 1998).  Mcm-2 is expressed abundantly throughout the cell cycle but is broken down 
rapidly on exiting the cycle or in quiescence
 
(Kearsey and Labib, 1998; Maiorano et al., 
1996; Musahl. et al., 1998) making it a reliable marker of cell cycle entry.  Whilst Ki-67 is 
more a more widely used proliferative marker, Mcm2 offers superior detection of actively 
replicating cells as Ki-67 fails to detect cell in most of G1 phase.  High Mcm2 expression has 
been shown to correlate with poor patient survival in diffuse large B-cell Lymphoma (Hou et 
al., 2011) and gastric carcinoma (Yang et al., 2012), whilst a higher expression is associated 
with better prognosis in colorectal carcinoma (Zhao et al., 2011) and high grade sarcoma 
(Matsubara et al., 2008).      
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Cyclin A, a 60kDa nuclear protein, acts as a surrogate marker of S-phase in mammalian 
eukaryotic cells that in astrocytomas is largely confined to S-phase (Scott et al., 2005).  In 
some cell lines, expression of cyclin A is maximal in S-phase with low expression in G2-
phase (Pines and Hunter, 1992).  The expression pattern, therefore, tends to vary with the 
type of cell or cell line, with some lines showing low level of cyclin A expression into early 
metaphase (Pines and Hunter, 1992; Xouri et al., 2007).  High cyclin A expression has been 
associated with poor prognosis in breast cancer in a study by Poikonen et al. however 
interestingly in this study, high Cyclin A was associated with a favourable response to 
anthracycline and antimetabolite chemotherapy although this did not impact on overall 
patient survival.  This is thought to be because Cyclin A labels cells in S-phase of the cell 
cycle and this fraction of cells togther with cells in G2/M phase are considered to be more 
sensitive to the effects of chemotherapy.  High cyclin A expression has also been reported to 
be associated with poor prognosis in pediatric embryonal brain tumours (Moschovi et al., 
2011).   
Geminin is a 25kDa protein whose nuclear expression is restricted to S-phase, G2-phase and 
the prophase and metaphase of mitosis (Madine and Laskey, 2001; Wohlschlegel et al., 2000; 
Wohlschlegel et al., 2002; Nishitani et al., 2001).  High Geminin expression has been 
reported to be associated with poor prognosis in small cell lung cancer (Haruki et al., 2011), 
salivary gland carcinoma (Yamazaki M et al., 2010), colorectal cancer (Nishihara et al., 
2009).    
Phosphorylated Histone H3 (PHH3) protein, though not a cyclin, is a useful marker that is 
present throughout mitosis (Shibata and Ajiro, 1993).  Phosphorylation at serine 10 of 
Histone H3 has been shown to correlate with chromatin condensation during mitosis and is a 
sensitive and specific marker of mitosis (Hendzel et al., 1997; Goto et al., 1999).  PHH3 
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Labelling indices (LI) are known prognostic factors in tumours like breast cancer (Skaland et 
al, 2009), malignant melanoma (Ladstein et al, 2012) and meningiomas (Kim et al., 2007).   
1:9) Cell Cycle phase distribution in Glioblastoma: 
Expression of Mcm-2, cyclin A and geminin have been investigated previously in 
oligodendrogliomas (Wharton. et al., 2004) and astrocytomas (Scott et al., 2005; Hara et al., 
2008; Shresta et al., 2007; Margraf et al., 2011) and, although all these studies have reported 
increased expression of these markers with increasing tumour grade, a correlation with 
patient prognosis and treatment response has not been reported in the literature for 
glioblastomas.  Margraf et al. (2011) studied the expression of Mcm2 and PHH3 in pilocytic 
astrocytomas and found no significant association of either marker with prognosis.  Wharton 
et al reported expression of Mcmc2 and Geminin in 55 cases of oligodendrogliomas (25 
Grade II and 30 Grade III) and observed increased expression of Geminin with increasing 
tumour grade.  Scott et al. analysed expression of multiple cell cycle markers in astrocytomas 
and found the expression of Mcm2, Cyclin A and PHH3 increased with increasing tumour 
grade but the expression of these markers did not correlate with patient survival.  Of note is 
the study by Shresta et al. (2007) who investigated the expression of Geminin in 51 cases of 
high grade astrocytomas (19 anaplastic astrocytomas and 31 glioblastomas) and although 
they reported an improved survival with higher geminin LI, on further analysis, the 
prognostic significance was only observed in the whole group and in anaplastic astrocytomas 
but not in Glioblastomas.  Interestingly, Coleman et al. (2006) found a positive association 
between PHH3 LI and survival in a study involving 103 patients with grade II and III 
astrocytomas.  However, a recent study by Habberstad et al. (2011) involving twenty seven 
patients with anaplastic astrocytomas found no significant correlation between PHH3 LI and 
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overall survival on Kaplan Meier analysis, although the small cohort size may be an issue 
(Habberstad et al., 2011).   
 In this thesis, Mcm2, Cyclin A, Geminin and PHH3 expression in glioblastomas have been 
investigated and the expression correlated with patient survival and response to adjuvant 
treatment.  It is possible that identification of a subpopulation of glioblastomas with a high 
replicative fraction may isolate a group of tumours that are more susceptible to therapies 
dependent upon active replication for their efficacy (Sallinen et al., 1994).  This in turn can 
provide clinicians with prognostic information and can aid in clinical decision making 
particularly in equivocal cases.    
1:10) Apoptosis 
Apoptosis or programmed cell death (Lockshin and Williams, 1965) type I (PCD I) is an 
important component of normal development and health of multicellular organism.  
Dysregulation of apoptosis is involved in various steps in the pathogenesis and progression of 
cancer, including increase in tumour size due to reduction in programmed cell death, 
accumulation of genetic instability and resistance to ischemia, chemotherapy and 
radiotherapy.  
1:11) Pathways of apoptosis 
Apoptosis is a tightly scripted death programme which results in activation of multiple 
groups of proteases and nucleases which breakdown various components of the cell including 
nuclear lamina, parts of cytoskeleton and DNA.  The process is characterized by certain 
morphological features (Kerr et al., 1972).  Upon induction of apoptosis, cells shrink due to 
breakdown of actin and laminins in the cytoskeleton.  The nucleus condenses following 
breakdown of chromatin and often takes a “horse-shoe” appearance.  The cells loosen from 
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neighbouring cells and eventually package themselves into a form by means of plasma 
membrane changes that allows for phagocytosis by macrophages, or allows the apoptotic 
cells to be engulfed by neighbouring cells or extruded from the tissue.  The latter stages are 
characterized by formation of membrane blebs and blisters processes.  Also characteristic but 
not universal, is the appearance of small vesicles called apoptotic bodies.    
Apoptotic cell death is mediated through intracellular (osmotic stress, DNA damage) and 
extracellular cues (growth factor withdrawal, matrix detachment and direct cytokine mediated 
killing).  Two main pathways of apoptosis are recognized.  The extrinsic pathway is death 
receptor mediated whereas the intrinsic pathway is mediated via the mitochondria.   
Both pathways involve a family of cysteine aspartate-specific proteases called caspases 
(Daniel and Korsmeyer, 2004).  Caspases are synthesized as inactive zymogens or Pro-
caspases and consist of a variable length pro-domain, a smaller p10 unit and a larger p20 unit.  
Caspase activation involves proteolysis at specific asparagines residues resulting in 
generation of an activated caspase which is a heterotetramer of two p10 and two p20 
subunits.  Apoptotic caspases are functionally divided into initiator caspases (Caspase 2, 8, 9 
and 10) and effector or “executioner” caspases (Caspase 3, 6 and 7) (Adams, 2005).   
Caspases are inactivated by Inhibitor of Apoptosis proteins (IAPs).  These include XIAP, 
cIAP1, cIAP2, ILP2, ML-IAP, NIAP, SUVIVIN and BRUCE (Krastad and Chekenya, 2010).  
These proteins inhibit apoptosis by binding to and directly inhibiting Caspase 9 in the 
intrinsic pathway and also to downstreamj effector caspases 3 and 7.  In addition they also 
promote caspase degradation by via ubiquitin-proteosome pathway.  (Verhagen et. al., 2002; 
Srinivasula and Ashwell, 2008; Krastad and Chekenya, 2010).    
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1:12) Intrinsic pathway 
The intrinsic pathway of apoptosis is triggered by a number of factors including UV or 
gamma radiation, growth factor withdrawal and chemotherapeutic drugs.  The central event 
in this pathway is mitochondrial outer membrane permeabilization (MOMP).  MOMP leads 
to release of multiple proteins from the mitochondrial intermembrane space (IMS) into the 
cytoplasm.  MOMP results in release of pro-apoptotic factors from the IMS.  These include 
cytochrome c, AIF (Apoptosis inducing factor), Smac/DIABLO, endonuclease G and 
omi/htra2.  Cytochrome c in association with APAF-1 (Apoptotic protease activating factor-
1) and dATP form Apoptosome.  The apoptosome then activates caspase-9 which in turn 
leads to activation of effector caspases in particular caspase 3 and commits the cell to 
apoptotic death.  Caspase 3 then cleaves the inhibitor of caspase-activated DNA (ICAD) 
activating CAD which then breaks DNA into fragments.  Smac (Diablo) and HtrA2 (Omi) 
facilitate caspase activation by inhibiting inhibitors of apoptosis proteins, which are 
endogenous caspase inhibitors (Wolf and Green, 2002; Wang, 2001).        
Members of Bcl-2 (B-cell lymphoma) protein family are important regulators in MOMP.  
The Bcl-2 family of proteins share sequence in 4 alpha-helical Bcl-2 homology (BH) regions, 
namely BH1, BH2, BH3 and BH4.  The Bcl-2 proteins can be divided into two groups, pro-
apoptotic and anti-apoptotic members 
The pro-apoptotic members are subdivided into two main groups. Bax and Bak share BH1, 
BH2 and BH3 domains.  Bid, Bim, Bik, Bad, Bmf, Noxa, Puma and Hrk are homologous in 
BH3 domain only (Tsujimoto, 2003; Danial et al., 2004).  The BH3 only proteins are further 
subdivided into activator pro-apoptotic members including Bid and Bim and sensitizer pro-
apoptotic members including Bad, Bik, Bmf, Hrk, Noxa and Puma.   
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The anti-apoptotic members include Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Bfl-1 and these share 
homology in all BH1-BH4 domains.   
Upon cytoskeleton or DNA damage or other apoptotic stimulation, BH3 only proteins 
including Bid and Bim are activated.  Bid and Bim acting as death signal sensors then lead to 
oligomerization of Bax and Bak and antagonize the anti-apoptotic effects of Bcl-2, Bcl-xl and 
other anti-apoptotic members of Bcl-2 family.  Bax and Bak then mediate MOMP by protein-
conducting pore formation in mitochondrial outer membrane (Wei, 2001).   The levels of pro- 
versus anti-apoptotic BCL-2 proteins play a critical role in regulating the apoptotic process 
(Lessene et al., 2008; Krastad and Chekenya, 2010).  
 
Figure 1.10:  The mitochondrial pathway of apoptosis with involvement of 
different pro-apoptotic and anti-apoptotic proteins with the central event being 
the process of mitochondrial outer membrane permeabilisation (MOMP).  
(Spierings et al., 2005) 
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1:13) Extrinsic pathway 
The extrinsic pathway of apoptosis begins with activation of certain death receptors e.g. 
Tumour necrosis factor receptor (TNFR) superfamily, by corresponding ligands e.g. Fas, 
TNF.  These receptors are characterized by the presence of an intracellular death domain and 
upon appropriate stimulation undergo oligomerization.  The activated receptors then form a 
death-inducing signalling complex (DISC) in association with a death domain containing 
adaptor molecule FADD (Fas associated death domain), procaspase 8 and the cellular 
FLICE-inhibitory proteins (FADD-like IL-1β-converting enzyme inhibitory protein (c-FLIP).  
The type of further response divides this pathway into two types.  In type I cells, this leads to 
extensive activation of caspase 8, sufficient to activate downstream execution or effector 
caspases 3 and 7.  These effector caspases subsequently target various cytoskeleton and 
nuclear substrate proteins, a step leading to culmination of apoptotic cell death.   
In type II cells, extrinsic or death receptor mediated apoptosis leads to MOMP via the BH3 
protein Bid.  Activated Caspase 8 can cleave Bid to form truncated-Bid (tBid) which can 
activate Bax and Bak leading to MOMP leading to release of cytochrome C and Apoptosome 
formation followed by activation of caspase 9.  Activated caspase 9 then leads to activation of 
effector caspases 3 and 7.  This pathway leads to apoptotic signal amplification in cells 
characterized by low levels of DISC and active caspase 8 (Scaffidi et al., 1998; Krastad and 
Chekenya, 2010).      
1:14) Apoptosis and Glioblastoma 
Dysregulation of apoptosis is a major contributor to the pathogenesis and progression of 
tumours in many ways.  (Stenner-Liewen and Reed, 2003) 
1. Failure of normal cell turnover leads to cell accumulation 
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2. Genetic instability and oncogene activation accumulates 
3. Increased resistance to immune attack 
4. Resistance to chemotherapy and radiotherapy 
5. Resistance to hypoxia and angiogenesis based targeted therapies 
6. Cellular survival in a detached state contributes to metastasis 
Apoptotic pathways in glioblastomas are subject of ongoing research.  Kuijlen et al. (2006) 
studied the expression of TRAIL (Tumour necrosis factor Related Apoptosis Inducing 
Ligand) and TRAIL receptors in a series of 62 patients with primary glioblastoma, and found 
an independent correlation between its expression and patient survival.  Studies investigating 
Bcl-2 expression in glioblastomas have led to contrasting results both in terms of expression 
and correlation with patient prognosis.  Strik et al. (1999) reported an up-regulation of Bcl-2, 
Bcl-xl and Mcl-1 and down regulation of Bax in recurrent glioblastomas independent of 
treatment (Strik et al., 1999).  In contrast, Martin et al. (2002) reported increased Bcl-2 and 
Bax expression in low grade astrocytomas and low expression in glioblastoma when studied 
by immunohistochemistry and vice versa on immunoblotting, indicating that the proteins are 
expressed at different levels in the cell.  The same study found no difference in Bcl-xl 
expression between low grade astrocytomas and glioblastomas.  Overexpression of Bcl-2 or 
Bcl-xl in glioblastoma cell lines leads to resistance to apoptosis and has also been linked to 
increased tumour cell motility (Wick et al., 1998).  This leads to enhancement of tumour cell 
migration and invasion by altering the expression of a set of metalloproteinases and their 
inhibitors (Wick et al., 1998, 2001, & 2004).  A series of studies have reported no correlation 
between Bcl-2 expression and patient survival (Kraus et al. 2001; Shrik et al., 1999; Martin et 
al., 2001).  Ruano et al. (2008)  found that several apoptosis genes are dysregulated in 
glioblastoma and negative expression of Bax correlates with adverse clinical outcome.  
Carlton et al. (2002), reported that N-truncated form of Bax; Bax-Gamma correlated with 
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longer survival in patients with glioblastoma.  From the above discussion, it can be inferred 
that higher expression of pro-apoptotic proteins (e.g., Bax and Bak) is likely to confer a 
survival advantage whereas an increased expression of anti-apoptotic proteins (e.g., Bcl-2 and 
Bcl-xl) is likely to be associated with poor prognosis.   
Caspase 3 immunohistochemical expression has been reported to correlate positively with 
increased tumour grade and early recurrence in intracranial meningiomas (Konstantinidou et 
al., 2007). Similarly Caspase 3 immunohistochemical expression has been associated with 
increasing tumour grade in gliomas but not significantly correlated with patient survival 
(Kobayashi et al., 2007).  While Caspase 3 is not strictly a “point of no return” on the route to 
apoptosis as further caspase activity can be inhibited by IAP, cIAP1 and Survivin (Salvesen 
and Duckett, 2002; Mellai and Schiffer, 2007), its place downstream in the apoptotic pathway 
makes it an indirect but effective marker of apoptosis (Mellai and Schiffer, 2007). 
This thesis has analysed the immunohistochemical expression of four members of the Bcl2 
family including Bcl2, Bcl-xl, Bax and Bak.  These proteins play a major role in 
mitochondrial pathway of apoptosis and as discussed previously, have an important role in 
oncogenesis.  The expression of final executioner caspase, Caspase 3, has been studied as an 
indirect marker of apoptosis.   
1:15) Autophagy 
The word autophagy derives from Greek words, “auto” oneself and “phagy” to eat.  
Autophagy refers to a cellular degradation pathway that involves the delivery of cytoplasmic 
substrates to the lysosomes.   Three forms of autophagy are described (Klionsky 2005; 
Reggiori 2012). These include chaperone mediated autophagy, microautophagy and 
macroautophagy. These forms are involved in different physiological functions and also 
differ in the mode of delivery of cytoplasmic substrates. 
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In eukaryotic cells, macroautophagy (herein referred to as Autophagy) is the main regulatory 
degradation pathway and is involved in breakdown of long lived proteins and cellular 
organelles (Klionsky 2005; Reggiori 2012).  Autophagy is a highly conserved multi-step 
pathway, in which cytoplasmic substrates sequestered inside double membrane vacuoles are 
delivered to lysosomes. This involves formation and expansion of an isolation membrane 
called phagophore, which then fuses to form a double membrane vesicle called an 
auotphagosome.  The autophagosome then fuses with a lysosome to form an 
autophagolysosome, where the sequestered cytoplamic substrate is then catabolized by 
lysosomal enzymes (Klionsky and Ohsumi 1999; Klionsky 2005; Reggiori et al., 2012).   
 
Figure 1.11:  Schematic model for formation of the autophagosome or Cvt 
vesicle.  In the model shown on the left, a membrane sheet from a pre-existing 
organelle such as Endoplasmic reticulum (ER) is induced to separate, undergo 
deformation and form a spherical shape that eventually seals.  In this model, no 
additional membrane is needed for subsequent vesicle expansion.  In the second 
model shown on the right, a portion of membrane forms the nucleus of the 
autophagosome or Cvt vesicle. In Yeast this nucleus is called Pre-
autophagosomal structure (PAS).  Additional membrane of unknown origin is 
then added to allow subsequent membrane expansion (Klionsky, 2005). 
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1:16) Autophagy Flux 
Autophagy flux refers to the complete process of autophagy including the delivery of 
substrate to lysosomes and its subsequent breakdown and recycling.  It is important to note 
here that autophagy is a dynamic, multistep process that can be positively and negatively 
modulated at several levels.  Monitoring autophagy flux requires cautious interpretation.  For 
example, an accumulation of autophagosomes could reflect either increased autophagosome 
formation due to increased autophagic activity or reduced turnover of autophagosomes.  The 
latter can be due to defective autophagolysome formation or inefficient degradation of 
substrate (Reggiori et al., 2012).   
1:17) Autophagy in cellular homeostasis 
Autophagy is involved in protein and organelle turnover and bulk degradation in virtually all 
cells and is regulated in accordance with the intracellular energy and nutrient demands, 
structural remodelling and in degradation of accumulated toxic cytoplasmic aggregates.  This 
makes it an important component of cellular homeostasis in basal conditions and an adaptive 
response in response to nutrient depletion, growth factor withdrawal, high energy demands 
and conditions of cellular stress, for example during infection, oxidative stress and protein 
aggregate accumulation (Shintani et al., 2004; Rubinsztein 2007).  This degradation of 
proteins generates amino acids which can then be used for de novo synthesis of proteins or 
together with fatty acids used to maintain cellular Adenosine Triphosphate production.  
Autophagy is been implicated in limitation of DNA damage and chromosomal damage, 
however, the precise mechanism and the extent of its role is unclear and subject of ongoing 
research.   
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1:18) Autophagy in cell death 
Autophagy under most circumstances is an important part of cellular adaptive pathway that 
promotes cell survival during periods of cellular stress.  Paradoxically it is also considered to 
be an important contributor to non-apoptotic cell death or Programmed Cell Death Type II 
(PKD II) (Bursch et al., 2004).  PKD II has a well defined phenotype characterized by 
abundance of autophagosomes and autolysosomes in the dying cell and differs from apoptotic 
cell death in that the dying cell is degraded by its own lysosomes rather than by phagocytosis.  
While Apoptosis or Programmed Cell Death type I is the main mechanism of cell death, 
certain stimuli or conditions seem to induce Autophagy or PKD II as the main mode of 
cellular demise.   Also, certain stimuli can induce either apoptosis or autophagy in a mutually 
exclusive way, possibly due to different thresholds required for both processes (Maiuri et al., 
2007).  
 
Figure 1.12: Autophagy and apoptosis can be induced by similar stressors in a 
context-dependent fashion.  The exact mechanism of this process is not known 
however it could involve different sensitivity thresholds of the two processes or a 
degree of mutual inhibition between the two processes.  Also in some cases a 
mixed phenotype can be detected.  The prime function of autophagy remains 
adaptation to cellular stress but massive autophagy can result in cell death.   
(Maiuri et al., 2007) 
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1:19) Autophagy pathway 
The process of autophagy is governed by a diverse set of protein encoded by Autophagy 
related genes (ATG).  Most of these genes have been characterized and studied in Yeast and 
subsequent studies have identified highly conserved mammalian homologues.  Thirty six 
ATG proteins have been identified thus far and 16 of these are essential for all autophagy 
related pathways.  Upon induction, specific ATG proteins govern a tightly regulated 
hierarchal process (Itakura and Mizushima, 2010; Suzuki et al., 2007).  This involves 
formation of the phagophore with subsequent expansion into an autophagosome (Xie and 
Klionsky, 2007; Yoshimori and Noda, 2008).  The proteins are classified into four groups.  
1. The Atg1/ULK complex 
2. The phosphatidylinositol 3-kinase (PI3K) complex 
3. The Atg9 trafficking system  
4. 2 parallel ubiquitin like conjugation systems. 
The Atg1/ULK complex comprises of Atg1, Atg 13 and Atg 17 in yeast with the mammalian 
equivalents being ULK1/2, Atg 13 and Atg 101.  The complex has a central role in induction 
of autophagosome biosynthesis and is a terminal target of various signalling cascades 
including TOR, insulin, PKA and AMPK pathways (He and Klionsky, 2009).  Activation of 
Atg1/ULK kinase induces and upregulates autophagy.  ULK kinases (ULK 1, 2 and 3) are 
stimulated through phosphorylation and dephosphorylation modifications of various subunits 
of the Atg1/ULK complex.  The PI3K complex in mammals exist in three forms: class I, II 
and III.  Class I and III are involved in autophagy whereas the function of class II is currently 
unknown.  Class I is involved in modulation of signalling cascades and Class III PI3K 
regulate organelle biosynthesis.  Class III PI3K has three common components hVps34, p150 
(Vps 15 in yeast) and Beclin 1 (Atg 6 in yeast).  The fourth component can be either Atg 14L 
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or UVRAG (Atg 14 and Vps38 in yeast respectively) (Itakura et al., 2008; Liang et al., 2006; 
Sun et al., 2008).    
 The Atg14L containing complexes work by directing the Class III PI3K complex I to 
phagophore to produce phosphatidyl-inositol-3-phosphate (PI3P) which in turn initiates 
recruitment of other Atg proteins.  Atg14L exist on endoplasmic reticulum in all states of 
autophagy (Matsunaga et al., 2010).  Upon induction of autophagy, Atg14L localizes to 
autophagosome membranes (Itakura et al., 2010).  Depletion of Atg14L reduces PIP3 
production and impairs formation of autophagosome precursor proteins and inhibits 
autophagy.  
 
Figure 1.13:  Autophagy pathway in mammals. a.) Autophagy can be induced via 
mTOR dependent or independent pathways which stimulate the nucleation and 
expansion of the phagophore/isolation membrane. b.) A multi-protein complex 
surrounding BECN1 with PI3K activity (mediated by PIK3C3) is important for the 
formation of the autophagosomal membrane. c.) Two ubiquitin-like modification 
systems are essential for mammalian autophagy;  ATG12 is activated by ATG7 (E1 
step), transferred to ATG10 (E2 step), conjugated to ATG5 and subsequently forms a 
complex with ATG16. This step is necessary early in autophagy for the formation of the 
phagophore or isolation membrane. MAP1LC3 (LC3) is cleaved by ATG4, activated by 
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ATG7 (E1 step), transferred to ATG3 (E2 step), and conjugated to the phospholipid 
phosphoethanolamine (PE). This form known as MAP1LC3-II (LC3-II), localizes to the 
autophagosome membrane and is subsequently degraded in the lysosome. ATG4 
cleaves off a C-terminal arginine (R) to expose a glycine residue that is then being 
linked to PE. Rapamycin (Rap) inhibits mTOR and activates macroautophagy, while 3-
methyladenin (3-MA) and wortmannin (WM) inhibit the PI3K activity and de-activate 
macroautophagy.  (Jaeger and Wyss-Coray, 2009) 
 
The UVRAG containing class III PI3K complexes interact primarily with the endosomal 
transport pathways.  UVRAG initially associates with BAR-domain protein Bif-1 which may 
regulate mAtg9 trafficking from the trans-Golgi network (TGN) (Takahashi et al., 2007; 
Takahashi et al., 2011).  UVRAG then promotes the fusion of autophagolysosomes with late 
endosomes and/or lysosomes by interacting with class C vps/HOPS protein complex.  Lastly 
UVRAG-containing class III protein complex binds to Rubicon, a late endosomal/lysosomal 
protein that reduces hVps34 activity and thereby suppresses autophagosome maturation.   
Of note, both Atg14L and UVRAG containing PI3K complexes interact through Beclin 1 
with Ambra 1, which in turn tethers these protein complexes to the cytoskeleton via an 
interaction with dynein.  Once autophagy is induced, ULK1 phosphorylates Ambra 1 thereby 
resulting in the release of Class III PI3K complexes from dynein (Bartolomeo et al., 2010; 
Fimia et al., 2007).  PI3K class III complexes then trigger autophagosome formation.  Ambra 
1 thus constitutes the direct regulatory link between Atg1/ULK1 and the PI3K complexes 
(Bartolomeo et al., 2010).   
Atg9 is a highly conserved transmembrane protein that is essential for autophagy.  It is 
distributed to the phagophore assembly site (PAS) and multiple additional cytoplasmic 
tubulovesicular compartments derived from the Golgi (Noda 2000; Ohashi and Munro 2010; 
Reggiori et al., 2004).  Atg9 is thought to act as membrane carrier providing lipid building 
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blocks for the expanding phagophore (Reggiori et al., 2004) and is one of the first factors to 
localize to PAS together with Atg1/ULK and PI3K complexes. 
Two closely interconnected ubiquitin-like proteins Atg12 and Atg8/microtubule-associated 
protein (MAP1)-light chain 3 (LC3) form part of the core autophagy machinery (Ichimura, et 
al., 1998; Mizushima et al, 1998; Yang and Klionsky, 2010).  Atg12 is conjugated to Atg5 
through the activity of Atg7 (E1-like) and the Atg10 (E2-like) enzymes.  The Atg12-Atg5 
conjugate then interacts with Atg16 which then oligomerizes to form a large multimeric 
complex.  Atg4 protease cleaves the C-terminus of Atg8/LC3 and generates a cytoplasmic 
LC3-I with a C-terminal glycine residue. LC3 I then conjugates to phosphatidylethanolamine 
(PE) in a reaction that requires Atg7 and the E2 like enzyme Atg3.  This generates LC3 II, a 
lipidated form which is attached to both faces of the phagophore membrane.  Once the 
autophagosome is formed, Atg4 removes LC3 II from the outer autophagosome surface.   
The two systems are partially overlapping and closely interconnected.  The multimeric 
Atg12-Atg5-Atg16 complex localizes to the phagophore and acts as an E3-like enzyme 
determining the site of Atg8/LC3 lipidation.  On the other hand, Atg8/LC3 lipidation is 
essential for optimal function of the Atg12 conjugation system.  There is also evidence to 
suggest that these two conjugation systems function together during expansion and closure of 
the phagophore.   
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Figure 1.15:  Atg proteins and their interaction to form autopgaosome in response 
to mTORC1 or other environmental cues.  (Regiorri et al., 2012).   
 
Recent evidence suggests that autophagy is a highly selective process relying upon specific 
cargo-recognizing autophagy receptors which connect the cargo to the autophagic 
membranes.  Autophagy receptors are proteins capable of interacting with autophagosome 
cargo and the Atg8/LC3 family members through a specific (WxxL) sequence (Noda et al., 
2008), called LC3-interacting region (LIR) motif or LC3 recognizing sequence (LRS).  The 
autophagy receptors interact with specific adaptors which in turn function as scaffolding 
proteins that bring the cargo-receptor complex in contact with the core Atg machinery and 
allows for specific sequestration of the substrate.  Here, it is important to note that that the 
selective types of autophagy rely on the same molecular core machinery as non-selective 
(starvation-induced) bulk autophagy.  Also it seems that the autophagy receptors and 
specificity receptors are not required for non selective autophagy (Reggior, et al., 2012).   
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1:20) AKT/mTOR pathway 
An important regulator in the autophagy pathway is mTOR (mammalian target of 
Rapamycin) which directly phosphorylates Atg 13 thereby modulating its binding to Atg 1 
and Atg 17. Inactivation of TOR leads to rapid dephosphorylation of Atg 13 which increases 
Atg1-Atg13-Atg17 complex formation which in turn stimulates Atg 1 kinase activity leading 
to induction of autophagy (Kamada et al., 2000; Yang, and Klionsky, 2009).   Thus the 
activated PI3K/AKT/mTOR pathway negatively regulates autophagy.  The activity of the 
PI3K/Akt and the mTOR pathway is often constitutively up regulated in tumours as a result 
of stimulation by growth receptors and mutations of the PTEN (Phosphatase and Tensin 
homologue deleted on chromosome ten) tumour suppressor gene.  The tumour suppressor 
activity of PTEN is mainly implemented through its inhibitory effect on the PI3K-dependent 
activation of Akt signalling (McCubrey et al., 2006). 
As discussed previously, class III PI3K plays a role in early stages of autophagosome 
formation.  Class I PI3K activity inhibits autophagy and its effect is partly mediated via the 
mTOR pathway.  
In addition, Beclin 1 which is a part of Class III PI3K complex, also binds Bcl-2 pro-
apoptotic family members (Pattingre and Levine, 2006).  It is interesting to note here that the 
interaction of Beclin 1 with class III PI3K stimulates autophagy and inhibits oncogenesis 
while its interaction with Bcl-2 inhibits autophagy and stimulates oncogenesis (Pattingre and 
Levine, 2006).   
1:21) p62 and autophagy 
One of the best studied mammalian autophagy receptors is p62/sequestosome 1 (SQSTM1).  
It binds ubiquitinated protein aggregates through an ubiquitin associated (UBA) domain and 
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to LC3 via LIR motif.  This triggers aggregate formation through the oligomerization of p62 
via its Phox and Bem1p (BP1) domain, thereby promoting specific autophagic degradation of 
ubiquitinated proteins.  Ubiquitination of proteins and organelles serves as a signal for 
recognition by p62 which are then themselves degraded together with the associated 
substrate.   P62 has been implicated in degradation of other substrates for example bacteria, 
viral capsid proteins, peroxisomes, damaged mitochondria and bacteriocidal precursor 
proteins.  Suppression of autophagy leads to accumulation of p62 in large aggregates which 
are also positive for ubiquitin (Komatsu et al., 2007; Nezis. et al., 2008).  P62 inclusion 
bodies have been detected in neurodegenerative conditions, liver disorders and also cancer, 
including malignant gliomas (Zatloukal et al., 2002, Moscat and Diaz-Meco, 2009).    
Recent evidence points to a much more central role of autophagy in tumour cell biology with 
influences on cell growth, survival and mitosis.  It biochemically links nutrient sensing to 
signalling cascades that regulate inflammation and reactive oxygen species (ROS) levels, an 
important mechanism for tumour cell survival  in conditions of autophagy defect (Moscat and 
Diaz-Meco, 2012).  Also recent evidence points to a role of p62 in cell cycle transit by means 
of its interaction with CDK1 (Moscat and Diaz-Meco, 2012). 
1:22) Autophagy in Glioma  
Resistance to apoptosis is characteristic of many cancer cells (Viktorsson et al., 2005; Ricci 
and Zong, 2006).  This has implications not only for tumourogenesis but also resistance to 
treatment including radiotherapy and chemotherapy (Okuda and Mak, 2004).   
Recent evidence suggests that gliomas are resistant to apoptosis or programmed cell death 
type I but seem to be less resistant to autophagic cell death or programmed cell death type II.  
Indeed Temozolomide, the most successful chemotherapeutic agent in glioblastoma, seems to 
work by inducing autophagic cell death in glioma cells rather than apoptosis (Kanzawa et al., 
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2004).  Kanzawa and colleagues demonstrated this in glioblastoma cell lines by 
demonstrating the induction of autophagy, recruitment of LC3 to autophagosome membranes, 
inhibition of tumour cell vibility and induction of G2/M arrest in malignant glioma cells 
when treated with clinically achievable dose of Temozolomide.  When autophagy was 
prevented in these cells at an early stage by PI3K inhibitor, LC3 localization to 
autophagosomes and antitumour effects of Temozolomide were suppressed.    
Other agents that induce autophagic cell death in cancer cells include tamoxifen, rapamycin, 
adenoviruses, and gamma irradiation (Ito et al., 2005; Paglin et al., 2001).  Radiotherapy and 
Temozolomide are important in this context as they are the mainstay of adjuvant treatment 
for glioblastoma.  Radiotherapy seems to induce autophagic cell death at least in glioma cell 
lines in vitro (Ito et al., 2005).  Temozolomide causes glioblastoma cells to undergo G2/M 
arrest and induce autophagic cell death (Kanzawa et al., 2004, Kanzawa et al., 2003).  Part of 
Temozolomide activity also seems to be by induction of late apoptosis.  This seems to be 
dependent on p53 and MGMT (methylated O
6
-methylguanine-DNA methyltransferase 
promoter) status.  Although contradictory, autophagy and apoptosis can be triggered by 
common upstream signals (LeFranc et al., 2007).  In certain circumstances apoptosis and 
autophagy can occur simultaneously whereas in other situations the cell switches between 
them in a mutually exclusive manner (LeFranc et al., 2007).    
1:23) Measurement of autophagy flux: 
Autophagy flux can be calculated by measuring the accumulation of autophagosomes as 
measured by electron microscopy image analysis, using green fluorescent protein (GFP) tag 
at the N-terminus, GFP-LC3, which is then reflected as an increase in punctuate dots under 
flouresecent microscope or western blot analysis of LC3 lipidation (conversion of LC3 I to 
LC3 II).  In mammals the LC3 subfamily contains LC3A, LC3B, LC3B2 and LC3C.  LC3 II 
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is the only protein marker that is reliably associated with completed autophagosomes and is, 
therefore, the most commonly used biomarker to calculate autophagy flux.  LC3B 
immunohistochemical expression has been described previously in glioblastoma (Aoki et al., 
2008). This thesis aims to investigate autophagy flux in glioblastoma by analysing the 
immunohistochemical expression of both LC3B and p62 in glioblastomas.   
1:24) Project aims: 
Glioblastoma oncogenesis is an area of active research and whilst our understanding of this 
subject continues to progress, the development of effective therapies remains slow and 
patient prognosis remains poor.  Markers of cell division cycle and apoptosis have been 
shown to be of prognostic and predictive value in other cancers, and the role of autophagy in 
oncogenesis is a subject of topical current research.  This thesis aims to analyse markers of 
cell division cycle, apoptosis and autophagy flux in Glioblastoma and to identify prognostic 
and/or predictive markers that can be employed in everyday practice to stratify and support 
clinical decision making in the management of patients with Glioblastoma.   
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Chapter 2 
Materials and Methods 
 
Ethical approval and patient consent – Collection of patient data - Tissue 
collection - Fixation - Processing - Paraffin embedding - Section cutting - 
Preparation of tissue micro-array - Haematoxylin and Eosin (H&E) 
staining - Immunohistochemistry for markers of apoptosis, autophagy and 
cell cycle phase - Quantification of immunohistochemistry results - 
Statistical analysis. 
  
2:1) Ethical Approval and patient consent:  
Approval to conduct the study was sought from the Local Research Ethics Committee, Hull 
and East Yorkshire Hospitals NHS Trust
1
.  This approval was initially obtained in 2002 to 
investigate the dysregulation of immune system in patients with intracranial tumours.  A 
further approval was obtained in 2008 to include research on markers of apoptosis and cell 
cycle phase distribution.  Patients were recruited following informed consent in accordance 
with the recommendations issued by the General Medical Council
2
.   
 
 
 
 
 
1
PIS/Studygroup/Version4 12/05/2008. Ww/CJB/JEP/10.04.00/version1/informed consent/r&ddept/ HEYHT 
2
General Medical Council – Research: The role and responsibilities of doctors, 2002. http://www.gmc-
uk.org/guidance/current/library/research.asp 
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2:2) Collection of patient data:  The data was collected on: 
 Patient demographics 
o Age 
o Sex 
 Pre-operative Karnofsky performance score 
 Date of diagnosis, taken as the date of first diagnostic biopsy  
 Date of surgery 
 Type of surgery (Based on surgeon’s observations recorded in the operative note) 
o Image guided biopsy 
o Debulking 
 Radiotherapy 
 Chemotherapy  
o PCV (Procarbazine, Lomustine and Vincristine) chemotherapy 
o Temozolomide chemotherapy  
 Date of death 
 Patient survival in days, calculated from the date of diagnosis 
 
The data was collected retrospectively for patients recruited to the study between 2002-
2007, using hospital notes, Neuro-oncology Multidisciplinary team meeting records, 
outpatient clinic letters and the information on Patient Centre
®3
.  Data was collected 
prospectively for patients recruited from June 2007 onwards.  All data was collected on 
Microsoft
®
 Excel spreadsheets and was stored in compliance with the Data protection Act 
1998
 4
.   
 
 
3
iSOFT PatientCentre 3.12.1102. Hull and East Yorkshire Hospitals NHS Trust intranet patient information 
software. 
4
Data Protection Act 1998. http://www.opsi.gov.uk/Acts/Acts1998/ukpga_19980029_en_1 
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2:3) Tissue collection:   
Tumour tissue was obtained from recruited patients intra-operatively and sent to the 
Neuropathology Unit at Hull Royal Infirmary for further diagnostic work.  Where possible, 
the tissue was sent fresh and upon receipt in the Neuropathology Unit, where feasible, 
approximately 1cm
2
 blocks of tumour tissue were snap frozen in a vial of liquid nitrogen and 
then transferred to a minus 75
o
C freezer (New Brunswick Scientific freezer, Scientific 
Laboratory Supplies).  The remainder of the tumour tissue was processed and embedded in 
paraffin wax as described later.  The frozen and paraffin embedded tissue were stored in the 
diagnostic archives of the Neuropathology Unit, Hull Royal Infirmary.  For the purpose of 
this research work, tissue blocks and stained diagnostic slides were removed and archived in 
accordance with the Human Tissue Act 2004
5
.  Stained research slides produced from the 
above material were catalogued and stored in locked cabinets at the Neuropathology Unit, 
Hull Royal Infirmary.     
 
2:4) Fixation:   
Neutral buffered formalin
6
 was used as for fixative for the biopsied tumour tissue.  
Depending on sample size, biopsies were fixed for 12-24 hours prior to processing and 
embedding. 
 
 
 
5
Human Tissue Act 2004. http://www.opsi.gov.uk/ACTS/acts2004/ukpga_20040030_en_1 
6
Neutral buffered Formalin: 40% formaldehyde 100ml, distilled water 900ml, sodium dihydrogen phosphate 
monohydrate 4g, disodium hydrogen phosphate anhydrous 6.5g. 
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2:5) Processing:   
Tissue processing allows tissue fixed in water based fixatives to be impregnated by paraffin 
wax.  The wax embedded tissue allows thin sections to be cut using a microtome.  This 
process involves the following steps: 
Dehydration:  This step moves the fixative and water from the tissue and replaces them with 
dehydrating fluid, usually using a series of alcohols of increasing concentration. 
Clearing:  This step involves the replacement of dehydrating fluid with a fluid that is totally 
miscible with both the dehydrating fluid and the embedding medium.  Chloroform is the 
agent used for clearing in our laboratory. 
 Impregnation:  The step replaces the clearing agent with the embedding medium. 
A typical automated 16 hour processing schedule, as used in our laboratory, is as follows: 
10% formalin starting solution (60 minutes), 70% alcohol (60 minutes), 90% alcohol (60 
minutes), Absolute Ethanol (4 cycles of 60, 90, 90 and 90 minutes), Chloroform (3 cycles of 
60 minutes), Histowax (Leica) (3 cycles of 90, 60 and 60 minutes).  Automated processing 
was performed using Leica TP1050 automated processing machine.   
 
2:6) Paraffin wax embedding:  Tissues were embedded in paraffin wax (Histowax, Leica) 
using a Leica EG1166 embedding station.  
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2:7) Section Cutting:  Sections of 4m thickness were cut using a cut using a rotary 
microtome (Leica RM2135).  The sections were cut onto coated glass slides
7
, dried on a hot 
plate and then transferred to a 37
o
C incubator till they were ready to be stained. 
 
2:8) Preparation of tissue micro-array:   
The tumour tissue blocks and slides were obtained from the diagnostic archive and were 
reviewed to ensure that the diagnosis of Glioblastoma conformed to the WHO 2007 
guidelines.  The representative tissue was identified by the author together with Dr IS Scott 
and the tissue slides and blocks were marked.  A tissue micro-array was then constructed by 
the author with a manual Tissue Micro-Arrayer
8
 using a 6mm needle. This was performed at 
the Neuropathology Department, Queen’s Medical Centre, Nottingham University Hospitals 
NHS Trust.  Sections (4µm) were then cut off the tissue micro-array block using a rotary 
microtome as described before. 
 
 
 
 
 
 
 
7
Superfrost
®
 Plus Slides, Menzel-Glaser, Menzel GMBH & Co KG, Braunschweig. 
8
Manual Tissue Arrayer 1, Beecher Instruments, Inc. USA. Supplied by Mitogen, UK. 
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2:9) Haematoxylin and Eosin (H&E) staining:   
The sections from the tissue micro-array on coated slides were heated on a hotplate for a 
minimum of 15 minutes, dewaxed in xylene over 5 minutes and then rehydrated by taking 
through a series of alcohols. The slides were stained with Gill III Haematoxylin
9
, rinsed in 
running tap water and differentiated with 1% acid alcohol
10
.  The sections were then rinsed in 
running tap water and blued in ammonia solution.  This was followed by counter stain with 
Eosin
11
.  The sections were then mounted in DPX
12
 (refractory index 1.52).  The H&E 
stained tissue micro-array slides were then analyzed to re-confirm the presence of 
representative Glioblastoma tissue in the arrays. 
 
 
 
 
 
 
 
 
 
09
Gill III Haematoxylin solution, Surgipath Europe Ltd. Peterborough, UK. 
10
Eosin Solution: Prepare a 1% solution of eosin and add a crystal of phenol to inhibit mould formation. Filter 
prior to use.  
11
1% Acid alcohol: 1% hydrochloric acid, 70% alcohol. 
12
BDH DPX mountant (VWR International, Poole, UK. Cat. No. 360294H) 
 57 
2:10) Immunohistochemistry for markers of cell cycle phase, apoptosis and autophagy:  
Formalin fixed, paraffin-embedded tissue micro-array tissue sections on coated slides were 
stained using a technique standard in the Neuropathology Laboratory at Hull Royal 
Infirmary.  The slides were heated on a hotplate for a minimum of 15 minutes, dewaxed in 
xylene over 5 minutes and then rehydrated by taking through a series of alcohols.  The slides 
were rinsed in running tap water and placed in a solution of 3% hydrogen peroxide
12
 in 
distilled water for 30 minutes to quench endogenous tissue peroxidase activity.  The slides 
were then placed in a slide bath containing antigen retrieval citrate buffer solution
13
 and 
antigen retrieval was carried out by heating the slide bath in a microwave oven at 800 Watt 
for 4 minutes and 150 Watts for 16 minutes.  Following antigen retrieval, the slides were 
rinsed with running cold water.  The slides were then loaded on cover plates, placed into 
Sequenza racks and rinsed in phosphate buffered saline
14
 (Bio-stat Diagnostics system) for 7 
minutes.  5% Normal goat serum
15
 in phosphate buffered saline (PBS) was then applied to the 
slides for 20 minutes to block non-specific antibody binding sites.  Primary monoclonal and 
polyclonal antibodies were prepared to appropriate dilutions in PBS and applied to the slides 
(Table 2:1).  The slides were incubated with primary antibodies at room temperature for 60 
minutes.  Following incubation, the slides were rinsed with PBS for 7 minutes. 
 
 
 
12
3% Hydrogen peroxide solution: 3ml of H2O2 (30% w/v, Merck, Germany) in 100ml distilled water. 
13
Antigen retrieval citrate buffer concentrate. Preparation by adding 10ml of the buffer concentrate to 1000ml of 
distilled water, adjust pH to 6.0±0.1. (Cat. No. HDSO5, HD Supplies, Aylesbury, Bucks)   
14
Phosphate buffered saline (Lot number 450040, J T Baker, London UK).  
15
Normal Goat Serum (Dako): Preparation by diluting in phosphate buffered saline to make a 5% solution. 
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Secondary antibody (Dako REAL
TM
 Envision
TM
/HRP. Rabbit/Mouse ENV)
16
 was then 
applied to the slides and the slides incubated for 30 minutes.  The slides were rinsed with 
PBS for 7 minutes and this was followed by application of DAB+ Chromogen
17
.  The slides 
were incubated with DAB for 5 minutes.  The slides were then rinsed in PBS and Copper 
sulphate solution
18
 was applied to the slides for 5 minutes following which the slides were 
rinsed again with PBS.  Following this, the slides were removed from the Sequenza racks, 
rinsed in running tap water and counter stained in Gill III Haematoxylin for 30 seconds.  The 
slides were then rinsed in running tap water, differentiated in 1% acid alcohol
19
 and blued in 
ammonia solution.  This was followed by dehydration of slides and mounting as described 
before.  Details of individual primary antibodies, their suppliers, optimal concentrations and 
positive controls are given in the table 2:1.  The immunohistochemical staining was 
performed by the author of the thesis.   
 
 
 
 
 
16
Dako REAL
TM
 Envision
TM
 Detection System, Peroxidase/DAB+, Rabbit/Mouse. Code K5007.  The kit 
contains:  
1. Dako REALTM Envision/HRP Rabbit/Mouse (ENV). Dextran coupled with peroxidase molecules and 
goat secondary antibody molecules against rabbit and mouse immunoglobulins. 
2. Dako REALTM Substrate Buffer. Bufferred solution containing hydrogen peroxide and preservative. 
3. Dako REALTM DAB+ Chromogen. 3,3’-diaminobenzidine tetrahydrochloride in organic solvent.  
17
20µl of DAB+ Chromogen in 1000µl of substrate buffer.   
18
Copper sulphate solution: 4g hydrated copper II sulphate, 7.2g sodium chloride in 1000ml of distilled water. 
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Antibody Name Cataloque No. Description Final 
Dilutions 
Positive 
control 
MCM-2 antibody CRCT2.1 
(D1.9H5) 
Abcam ab6153 Mouse monoclonal 1:150 Tonsil* 
Geminin antibody 
 
Abcam ab12147 Rabbit polyclonal 1:100 Tonsil* 
Cyclin A antibody [6E6] 
 
Abcam ab16726 Mouse monoclonal 1:50 Tonsil* 
Histone H3 (phospho S10) 
antibody – Mitosis Marker  
Abcam ab5176 Rabbit polyclonal 1:200 Tonsil* 
Bcl-2 Clone 124 
 
Dako Mouse Monoclonal 1:50 Tonsil* 
Bcl-xl Clone 2H12 Sigma Batch No. 
B9429-0.2mL 
Mouse monoclonal 1:100 Hodgkin’s 
Lymphoma 
Bax antibody 
 
Abcam ab10813 Rabbit polyclonal 1:500 Tonsil* 
Bak antibody 
 
Abcam ab32371 Rabbit monoclonal 1:200 Tonsil* 
Active and pro Caspase 3 
antibody 
Abcam ab47131 Rabbit polyclonal 1:1500 Tonsil* 
LC3b Abcam ab51520 Mouse monoclonal 1:2000 Renal cell 
carcinoma 
p62 BD transduction 
Lab 610833 
Mouse monoclonal 1:50 Renal cell 
carcinoma 
*The tonsil used as a positive control denotes to normal human tonsil tissue. 
Table 2.1: Antibody details and dilutions. 
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2:11) Quantification of immunohistochemistry results:   
The number of stained cells per high power field (X40 objective, magnification X400) were 
counted and a semi-quantitative labelling index was calculated for markers of cell cycle and 
apoptosis using the following formula.  
Labelling index (LI) = Number of stained cells per high power field/Total number of cells per 
high power field.   
At least 9 high power fields were counted for each case.  
The staining of LC3B and p62 was calculated using a semi-quantitative staining score.  Both 
cytoplasmic and nuclear staining was taken into account.  The staining score was zero if 
negative and from 2-5 if positive, based on a sum of cytoplasmic staining intensity (1-3) and 
percentage of nuclear staining (1:less than 50%, 2:more than 50%).  Staining score of 0-2 was 
considered as low and 3-5 as high protein expression.     
The slides were reviewed independently by the author of the thesis, Dr IS Scott and Mrs 
Catherine Hills and the inter-observer variation was less than 5%.   
2:12) Statistical analysis:   
SPSS
20
 version 20 software was used for Univariate statistical analysis on the labelling 
indices of markers of apoptosis and cell cycle phase. Cox regression and Kaplan Meier 
survival curves were then calculated to demonstrate the association between patient survival, 
response to treatment and markers of apoptosis and cell cycle phase. 
 
 
20
SPSS. Statistical Package for the Social Sciences. www.spss.com/s 
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Chapter 3 
Results – Markers of cell division cycle 
Cell cycle markers - Clinical data - Labelling Indices & Prognosis - 
Cell cycle markers in recurrent Tumours - Phosphohistone H3 
(PHH3) - Discussion 
 
3:1) Clinical data 
A total of 66 patients were included in the study between 2007-2009.  All patients underwent 
neurosurgical intervention in the form of either a biopsy or debulking surgery,  and were 
further subdivided into two groups based on the administration of adjuvant treatment.  In 
group 1 (n=50), all patients underwent surgery and radiotherapy  with 24 of these patients 
also receiving temozolomide chemotherapy. Of note, 84% (n=42) of this group of patients 
underwent debulking surgery.  Patients in group 2 (n=16) underwent surgery only,  as 
adjuvant treatment, although planned, was not offered due to poor post-operative 
performance score.   A similar percentage of patients in  this group  also underwent debulking 
surgery (87.5%, n=14).  Table 1 gives the clinicopathologic details of patients in the two 
groups.   It was observed that the two groups although not completely homogenous, have 
similar median age (61 years vs. 67 years) and similar percentage of patients undergoing 
debulking surgery (84% vs. 87.5%).  This is important because as noted in chapter 1, age and 
debulking surgery are important prognostic factors in Glioblastoma.   
There were three cases of recurrent tumour that were studied in greater detail.  Two of these 
patients underwent debulking surgery, radiotherapy and temozolomide chemotherapy.  The 
third patient underwent debulking surgery on three occasions and radiotherapy was 
administered after first surgery. 
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 Group 1 Group 2 
N 50 16 
Median age (yr) 61 67 
Male : Female 33 : 17 7 : 10 
Median Survival (days) 258 65 
Debulking surgery (number of patients) 42 14 
Preoperative median Karnofsky performance score 60 50 
Image guided biopsy (number of patients) 8 2 
Radiotherapy (number of patients) 50 0 
Temozolomide chemotherapy (number of patients) 24 0 
Table 3.1: Clinical data of patients in cell cycle marker study 
 
3:2)  Labelling Indices & Prognosis 
Representative array sections for each marker are shown in Figure 3.1.  The median labelling 
indices of all three markers for group 1 and 2 are summarised in Table 3.2.  The median 
Mcm-2 labelling index (LI) in group 1 was 36.7% Kaplan Meier analysis (Figure 3.2a) did 
not reveal any association of this factor with survival (Log Rank p= 0.522) although linear 
regression analysis did reveal a positive correlation with survival (p=0.0376).  The median 
value of cyclin A LI in Group 1 was 4.2% and Kaplan Meier analysis (Figure 3.2b) showed a 
survival advantage for patients with a higher LI (Log Rank p=0.0063) and linear regression 
analysis showed a positive correlation with survival (p=0.004).  The median level of geminin 
LI in Group 1 was 7.8%.  Kaplan Meier analysis (Figure 3.2c) demonstrated a survival 
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advantage on patients with a higher geminin LI (Log Rank p=0.0046).  Linear regression 
analysis showed a positive correlation between geminin LI and survival (p=0.0006).  Survival 
correlations are shown in Figure 3.4. 
In group 2, there was no statistically significant relationship between patient survival and LI 
for Mcm-2, cyclin A and geminin (Figure 3.3a-c), although an association between high 
geminin expression and poor survival was observed (Log Rank p=0.1325).  The survival 
correlation curves for Mcm2, Geminin and Cyclin A labelling indices in group I and 2 are 
illustrated in Figure 3.5. 
 
 
 Group 1 
(n = 50) 
Group 2 
(n = 16) 
Mcm2 36.7 (22.9-51.8) 43.8 (33.5-51.1) 
Cyclin A 4.2 (2.4-6.9) 4.8 (3.8-6.4) 
Geminin 7.8 (5.8-10.5) 7.6 (5.9-9.1) 
Table 3.2:  Median Labelling indices (%) with interquartile range of cell cycle 
markers in group 1and Group 2 
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3.1a
3.1b 
Glioblastoma - H&E 
Figure 3.1a-h: Representative tissue micro-array discs showing tumours in which there has been 
greater than median survival following adjuvant therapy (a, c, e, g) and tumours showing a poor 
response after adjuvant therapy (b, d, f, h).  Adjacent levels in the array are shown to allow 
comparison of similar areas of the tumour.  It can be seen that in tumours where there is a good 
response to adjuvant therapy, there is elevated cyclin A and Geminin expression indicating a greater 
proportion of cells actively progressing through the cell cycle.  The total number of cells in cycle is 
also greater (Mcm-2 expression).   
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3.1c
3.1d 
Glioblastoma - Cyclin A (S-phase) 
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3.1e
3.1f 
Glioblastoma – Geminin (S-phase, G2-phase and Mitosis) 
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3.1g
3.1h 
Glioblastoma - Mcm-2 (Cell Cycle Entry) 
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3.2a p=0.522 
3.2b p=0.0063 
3.2c p=0.0046 
Figure 3.2a-c:  Kaplan Meier survival curves for Mcm2, Cyclin A and Geminin in 
Group 1 (n=50).  Kaplan-Meier curves calculated on the basis of marker LI being 
greater than (green) or less than (red) the median level.  
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3.3a p=0.6209 
3.3b p=0.1325 
3.3c p=0.7847 
 
Figure 3.3a-c:  Kaplan Meier survival curves for Mcm2, Cyclin A and Geminin in 
Group 2 (n=16).  Kaplan-Meier curves calculated on the basis of marker LI being 
greater than (green) or less than (red) the median level.  
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 Figure 3.4:  Correlation curves for Mcm2, Geminin and Cyclin A LIs in Group 1 
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 Figure 3.5:  Correlation curves for Mcm2, Geminin and Cyclin A LIs in Group 2 
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3:3) Cell cycle markers in recurrent tumours  
In the three patients with recurrent tumour, the LIs of Mcm2, Cyclin A and Geminin reduced 
by more than 50% after administration of adjuvant treatment (radiotherapy and temozolomide 
in 2 cases and radiotherapy alone in the third case).  In the third case, the LIs of all three 
markers reduced after radiotherapy but these increased again by the time of third surgical 
procedure (figure 3.5). 
 
 
 
Figure 3.6: Mcm2, Cyclin A and Geminin labelling indices in three cases of recurrent 
Glioblastomas, (numbered 1, 2 and 3) and represented in three different colours.   The 
three biopsies are represented by a, b and c for each case (Only case 3 had three 
biopsies). 
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3:4)  Phosphohistone H3 (PHH3): 
Phosphohistone H3 (PHH3) is a marker of mitosis.  Analysis of PHH3 was performed in 30 
patients due to lack of representative tumour tissue micro-array cores.  A representative 
example of PHH3 immunohistochemical staining is shown in Figure 3.6.  The median LI for 
pH3 was 8.3% with an IQR of 4.5-13.7%.  On Kaplan Meier survival analysis, no significant 
correlation was observed between pH3 LI and patient survival (Log Rank p=0.819, figure 
3.7).  Linear regression also failed to show any significant relationship between PHH3 LI and 
patient survival (p=0.702, R
2
=0.0057, figure 3.8).  Here, it is important to note that the LIs of 
cyclin A and Geminin still correlated significantly with patient survival in these 30 patients 
(Log Rank p=0.004 and p=0.0006 respectively). 
 
 
Figure 3.7: IHC staining of Glioblastoma tissue with PHH3 identifying mitotic cells 
– (Objective 40X) 
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Figure 3.8: Kaplan Meier survival curve for PHH3. Kaplan-Meier curves calculated on the 
basis of marker expression being greater than (green) or less than (blue) the median level.  
Log rank p=0.819.   
 
 
Figure 3.9: Survival correlation curve for PHH3 LI 
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3:5) Discussion: 
Mcm-2 is a marker of cell cycle entry and is more inclusive than the widely used marker 
Ki67 in this regard because Ki67 fails to detect cells in the greater part of G1-phase (Scott et 
al., 2005).  Mcm-2 expression increases with increasing tumour grade in oligodendrogliomas
 
(Wharton et al., 2004) and astrocytomas
 
(Scott et al., 2005) and correlates well with the Ki67 
labelling index
 
(Wharton et al.,2004; Scott et al., 2005).  The expression of Ki-67 was 
therefore not studied in this thesis.  A high level of expression of Mcm-2, representing a 
proliferating population of cells in glioblastoma is not unexpected as these are biologically 
aggressive tumours and thereby represent an important challenge in terms of treatment.  No 
significant relationship between Mcm-2 expression and patient prognosis was identified 
however.  This is possibly due to the fact that Mcm-2 is expressed by all cells that have 
entered cycle.  It has been shown previously that a number of these cells will be stably 
arrested in the G1-phase of the cycle where they are not susceptible to adjuvant therapy 
(Scott et al. 2005).  Thus, a high Mcm-2 LI may not correlate with increased susceptibility to 
adjuvant therapy if a large proportion of the cells detected by this marker are arrested in G1-
phase.  It is a well established fact that radiation sensitivity varies with different phases of the 
cell cycle with cells at the G1/S transition and prophase of Mitosis being the most sensitive 
(Hama et al., 2003; Tersima & Tolmach, 1963).  These phases will be specifically detected 
by cells expressing cyclin A (S-phase) or geminin (S-phase through to Mitosis); markers that  
were found to correlate with survival following adjuvant therapy. 
In mammalian cells, cyclin-A expression is limited to the S-phase of the cell division cycle 
where it forms a complex with cdk2 and is important in the initiation of DNA 
replication(Pines and Hunter, 1992).  Cyclin-A expression has also been reported to increase 
with increasing tumour grade in astrocytomas (Scott et al., 2005) and higher expression has 
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been shown to correlate significantly with patient prognosis in low-grade astrocytomas but 
not in high grade astrocytomas (Shresta et al., 2007).  Here, an elevated level of cyclin-A 
expression was associated with improved patient survival only in patients receiving adjuvant 
treatment.  This suggests that an elevated S-phase fraction, as estimated by cyclin-A 
expression, predicts those tumours that are more sensitive to adjuvant treatment because they 
have an increased proportion of cells in S-phase, replicating DNA.  In patients not receiving 
therapy, a high cyclin A LI may be detrimental to survival as the tumour is likely to grow 
more rapidly.  Mammalian cells express nuclear geminin in S-phase, G2-phase and in mitosis 
until the stage where the nuclear membrane breaks down (Wohlschlegel et al. 2002).  
Increased geminin expression has been found in many types of human neoplasm including 
oral squamous cancer (Tamura et al., 2010), colorectal cancer (Nishihara et al. 2009), breast 
cancer (Gonzales et al., 2004), oligodendrogliomas (Wharton et al. 2004) and astrocytomas 
(Shresta et al., 2007).  High geminin expression has been demonstrated to correlate 
significantly with patient survival in anaplastic astrocytomas but not in glioblastomas 
(Shresta et al., 2007).  Again, this study demonstrated a strong association between geminin 
expression and patient survival, but only in patients who received adjuvant treatment.  In a 
similar way to that proposed for cyclin A, this correlation is likely to be because geminin is 
detecting actively proliferating cells; that population of tumour cells most sensitive to 
chemo/radiotherapeutic intervention.  The failure of these markers to predict survival in 
patients not receiving adjuvant therapy implies that the effect being detected is related to 
therapy rather than features relating to the intrinsic biology of the tumour.  Indeed, a high LI 
for cyclin A &/or geminin in untreated tumours confers an adverse prognosis due to rapid 
tumour growth.  Previous studies have suggested that geminin in tumour cells is most often 
present in a non-mutated form with a low mutation frequency and there is no evidence for 
amplification of the gene in breast cancer (Gonzales et al., 2004).  Thus it would appear that 
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the predictive properties of geminin expression are related to its normal biological function in 
cell cycle replication rather than a mutation or amplification causing loss of suppressor 
function; indeed, dysregulation of geminin during G1 may suppress tumour growth (Yoshida 
et al., 2004). 
Traditionally, counts of mitotic figures have been used to identify grade  in gliomas whereby 
increased number of mitotic figures suggests higher tumour grade and therefore poor 
prognosis.  However, mitotic figures only detect a subpopulation of cells in mitosis i.e., those 
that have progressed beyond the formation of metaphase plate.  Phosphohistone H3 (PHH3) 
is a surrogate marker of mitosis and overcomes this disadvantage by identifying cells in 
prophase; cells which are considered sensitive to effects of adjuvant treatment.  Mitotic figure 
counts and PHH3 LIs are known prognostic factors in tumours like breast cancer (Skaland et 
al., 2009) and malignant melanoma (Ladstein et al., 2012).   In this study, no significant 
correlation of PHH3 LI with patient survival was observed, both on Kaplan Meier analysis 
and linear regression.  PHH3 analysis was however possible in only 30 patients due to lack of 
representative tissue sample and this could have impacted on the results due to the relatively 
small cohort size.  It is important to note here that even in this cohort of 30 patients, Geminin 
and Cyclin A expression correlated positively with survival.    
The expression of Mcm-2, cyclin-A and geminin in the three recurrent cases decreased after 
the administration of adjuvant treatment.  This reinforces the above observations that the 
effects of adjuvant treatment is likely to be cell phase specific and the cell populations that 
are removed by treatment are those cells that are actively replicating.  The cell population in 
G1 does not appear to be affected by treatment.  In case 3, there was an increase in the 
expression of all three markers at the time of the third surgical procedure, suggesting that 
although radiotherapy was able to reduce the number of actively replicating cells at the time 
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of second surgery, the effect was not sustained,  suggesting biological recovery of the tumour 
after the cessation of therapy.  These data also provide a histological explanation for the 
common observation that the treatment effects, while effective in the initial stages, eventually 
fail to control the disease process. 
In summary, the data show that high cyclin-A and geminin expression in glioblastomas was 
able to predict post-operative survival following adjuvant therapy by identifying those 
tumours with a high S-phase fraction or proliferating cell component.  Cyclin A and geminin 
were superior Mcm-2 as markers of survival in these tumours, as Mcm2 also detect cells 
resident in G1-phase which are not actively proliferating and are thus contributing little to 
tumour growth.  The incorporation of geminin into diagnostic panels for glioblastoma is 
therefore likely to assist oncologists in the selection of appropriate adjuvant 
chemo/radiotherapy especially where the decision is equivocal or complicated on other 
grounds.   
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Chapter 4 
Results – Markers of apoptosis 
Markers of Apoptosis – Discussion 
 
4:1)  Markers of Apoptosis: 
Due to the limitation of available representative tumour tissue micro-array cores, markers of 
apoptosis  could only be analyzed in 28 patients.  The clinical details of these patients are 
summarized in table 4.1.  A total of 5 apoptotic markers were used: Bcl2, Bcl-xl, Bak, Bax 
and Caspase 3.  The representative examples of glioblastoma immunohistochemical staining 
are illustrated in Figures 4.1 a-e.   
N 28 
Median age (yr) 61 
Male : Female 17 : 11 
Median Survival (days) 258 
Debulking surgery (number of patients) 25 
Preoperative median Karnofsky performance score 70 
Image guided biopsy (number of patients) 3 
Radiotherapy (number of patients) 24 
Temozolomide chemotherapy (number of patients) None  
Table 4.1:  Clinical data in patients in apoptotic markers study 
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Bax staining was too diffuse to be considered as credible staining (figure 4.1c) and in spite of 
using antibodies from 2 different sources, different dilutions and different 
immunohistochemistry protocols, the staining was not deemed to be quantifiable.  Bcl2, Bcl-
xl, Bak and Caspase 3 produced specific cytoplasmic staining (figures 1b-1d) and the 
labelling indices were calculated as detailed in Table 4.2.   
Fig 4.1a: Bcl2 
Fig4.1b: Bclxl 
 Fig 4.1c: Bax 
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Fig 4.1d: Bak 
Fig 4.1e: Caspase 3 
Figures 4.1a-e:  Representative examples of Glioblastoma IHC staining with Bcl2, 
Bcl-xl, Bax, Bak and Caspase 3 (Objective 10X).   
 
 Labelling Index % with interquartile range 
Bcl2 8.1 (2.3-11.8) 
Bcl-xl 1.84 (0.87-3.7) 
Bak 16.1 (6.9-25.2) 
Caspase 3 50.2 (34.56-72.9) 
Table 4.2: Median Labelling indices (%) with interquartile range of apoptosis 
markers 
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The survival correlation curves of Bcl2, Bcl-xl, Bak and Caspase 3 labelling indices are 
shown in Figure 4.2.  On Kaplan Meier survival analysis only, Bak LI correlated significantly 
with patient survival (Log rank p=0.0039, Figure 4.3c) with Bal LI values above median 
conferring a survival disadvantage.  Linear regression Bcl2, Bcl-xl and Caspase 3 Labelling 
indices did not correlate with patient survival (Figure.  4.3a, 4.3b, 4.3d, table 4.3). 
 
 
 
 
 
Figure 4.2: Survival correlation curves for Bcl2, Bcl-xl, Bak and Caspase 3 labelling 
indices 
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4.3a
4.3b
 84 
4.3c
4.3d 
Figures 4.3a-d:  Kaplan Meier survival curves for Bcl2, Bcl-xl, Bak and Caspase 3 LIs. 
Kaplan-Meier curves calculated on the basis of marker LI being greater than (green) or 
less than (blue) the median level.   
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 Log rank  
(p value) 
Linear regression  
(p value) 
Bcl2 0.166 0.389 
Bcl-xl 0.876 0.307 
Bak 0.0039 0.011 
Caspase 3 0.596 0.869 
Table 4.3:  Log rank and linear regression p values for markers of apoptosis 
 
4:2) Discussion: 
The sample size for analysis of apoptosis was limited to 28 patients due to lack of 
representative tumour tissue.   The labelling indices for two anti-apoptotic (Bcl-2, Bcl-xl) and 
two pro-apoptotic (Bax, Bak) members of the Bcl-2 protein family were analysed.  Bcl-2 and 
Bcl-xl over-expression in glioma cell lines  has been shown to be linked with increased 
tumour cell motility and resistance to apoptosis (Wick et al. 1998).  Also, Bcl-2 inhibitor 
ABT-737 was shown recently to induce apoptosis in glioblastoma cells both in vivo and in 
vitro by inducing the release of BAX from its partner Bcl-2 (Tagscherer et al. 2008).  Bcl-2 
and Bcl-xl protein expression, however, had not been significantly correlated with survival by 
previous investigators (Martin et al., 2001; Kraus et al., 2001; Strik et al., 1999).  In keeping 
with the existing literature, no significant correlation between Bcl-2 and Bcl-xl LIs with 
patient survival was observed in the current study.  Whilst this could be due to the small 
sample size of the study, an important point in this regard is the observation made by Martin 
et al. (2002) who observed low expression of Bcl2 and Bax in glioblastoma with 
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immunohistochemistry but vice versa on immunoblotting suggesting a differential expression 
of these proteins in different cells.   
Negative expression of pro-apoptotic Bax protein has been linked to adverse clinical outcome 
by Ruano et al (2008) in a DNA microarray study study on 20 Glioblastoma samples.  Here 
problems were encountered with quantification of Bax immunohistochemical staining.  This 
was in spite of trying two different antibodies from different sources and using different 
immunohistochemistry protocols.  This could be due to the fact that Bax exists in different 
isoforms (Cartron et al., 2003) and current available antibodies are unable to differentiate 
between the different isoforms thereby producing a diffuse cytosolic staining which is 
difficult to quantify.   
Bak is an important pro-apoptotic member of the Bcl-2 family that plays a role similar to Bax 
in the intrinsic pathway of apoptosis.  Bak protein expression has been studied in 
glioblastoma tissue (Cartron et al., 2003) and glioblastoma cell lines (Cartron et al., 2003; Jin 
et al., 2006).  Cartron and colleagues have described the severe impairment of the apoptotic 
pathways when glioblastoma cell lines were deficient in both Bax and Bak.  There are 
however no studies which have correlated Bak protein expression with survival.  The current 
study, a significant correlation of Bak expression with patient survival with higher expression 
of Bak correlating with poor prognosis, in spite of the small sample size was discovered.  
This result is contrary to what was expected as increased Bak expression has been previously 
shown to be associated with increased sensitivity to apoptosis - inducing therapies which in 
turn translates in to enhanced patient survival.  The results will therefore have to be verified 
by studying the protein expression in a larger sample size and with other methods.  These 
results may suggest a so far unknown role of Bak in glioblastoma oncogenesis and therefore 
needs to be investigated further. 
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Caspase 3 is the final effector caspase in the apoptosis pathway and its position as the last 
common step in apoptotic pathway makes it a useful indirect marker of apoptosis (Mellai et 
al., 2007).  Increased immunohistochemical expression of caspase 3 has been associated with 
increasing tumour grade and early recurrence in meningiomas (Konstantinidou et al., 2007).  
In gliomas, immunohistochemical analysis of caspase 3 expression increases with increasing 
tumour grade but no significant correlation with prognosis has been observed (Kobayashi et 
al., 2007).  Here, in agreement with previous work no correlation of caspase 3 LI with patient 
survival was observed.  Here it is important to note that Kobayashi et al. have used an 
antibody specific to cleaved caspase 3 in 21 patients with glioblastoma whereas the antibody 
used in this project identifies both the pro- and cleaved or activated form of caspase 3.  Also 
important to note is that Vakkala et al. used an antibody similar to ours but use a staining 
score system rather than a labelling index,   the former is generally considered to be a lot 
more subjective.  Based on the results in this thesis, a study on larger number of patients with 
an antibody against the cleaved form of caspase 3 is recommended. 
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Chapter 5 
Results – markers of autophagy flux 
Markers of autophagy flux – Autophagy markers in Giant 
cell glioblastoma – Autophagy markers in recurrent 
glioblastoma - Discussion 
 
5:1) Markers of Autophagy  
Immunohistochemical staining of autophagy flux markers, LC3b and p62, was analysed in 45 
of the total 66 patients, due to lack of representative tumour tissue cores.  Of the 45 patients, 
39 patients underwent debulking surgery.  All patients had cranial irradiation and 20 patients 
received temozolomide.  The clinical details are summarized in Table 5.1.   
 
N 45 
Median age (yr) 61 
Male : Female 30 : 15 
Median Survival (days) 269 
Debulking surgery (number of patients) 39 
Preoperative median Karnofsky performance score 60 
Image guided biopsy (number of patients) 6 
Radiotherapy (number of patients) 45 
Temozolomide chemotherapy (number of patients) 20 
Table 5.1:  Clinical data of patients in Autophagy markers study 
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Representative microarray immunohistochemical staining of LC3B and p62 is illustrated in 
Figure 5.1.  LC3B and p62 staining was quantified as described in chapter 2 and figure 5.1 
also demonstrates the representative samples for each criterion in the quantification method.  
LC3b and p62 have similar staining characteristics and a significant correlation was observed 
between LC3b and p62 staining scores (Linear regression p=0.001, R
2
=0.22, Figure 5.2).  
 
   LC3B   p62 
Cytoplasmic 
staining Intensity 1 
  
Cytoplasmic 
staining Intensity 2 
  
Cytoplasmic 
staining Intensity 3 
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Nuclear staining 
<50% 
  
Nuclear staining 
>50% 
  
 
Figure 5.1: Immunohistochemical staining of LC3B and p62 IN Glioblastoma cores 
(Objective 10X).  Illustrated are examples of each criteria used in calculating the 
staining score oh LC3B and p62 staining scores. 
 
 
Figure 5.2: Correlation between p62 and LC3b staining scores. Linear regression p=0.001. 
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The survival correlation curves for the staining scores of both markers are shown in figure 
5.3.  Linear regression analysis did not show any significant relationship between p62 and 
LC3b staining scores with survival (p=0.29 and p=0.92 respectively).  Kaplan Meier survival 
analysis revealed a significant negative relationship between raised p62 staining score and 
patient survival (Log rank p=0.017, figure 5.4a). LC3b staining score however did not 
correlate significantly with patient survival on Kaplan Meier analysis (Log rank p=0.68, 
Figure 5.4b).   
 
 
 
Figure 5.3:  Survival correlation curves for LC3B and p62.  
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Fig 5.4a 
Fig. 5.4b 
Figure 5.4: Kaplan Meier survival curves for LC3b and p62.  Kaplan-Meier curves 
calculated on the basis of marker staining score being greater than (green) or less 
than (red) the median level.  
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5:2) Autophagy markers in Giant cell Glioblastoma 
In this regard, an interesting finding was the distinct and heavy staining patterns of both LC3b 
and p62 observed in Giant cell glioblastomas as illustrated in Figure 5.5.  Giant cell 
Glioblastomas have a worse prognosis as compared with the usual glioblastoma phenotype 
and the suggested survival disadvantage for higher p62 staining score would be in keeping 
with this.   
 
   LC3B  p62 
Usual 
glioblastoma 
  
Large cell 
glioblastoma 
  
 
Figure 5.5: Staining patterns of LC3B and p62 in usual and Giant cell Glioblastoma 
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5:3) Autophagy markers in recurrent tumours: 
Analysis of LC3B and p62 staining scores in the three cases of recurrent glioblastoma did not 
show any significant variation (Figures 5.6 and 5.7).  As described in Chapter 3:1:1, case 1 
and case 2 underwent debulking surgery, radiotherapy and temozolomide chemotherapy.  
Case 3 underwent debulking surgery on three occasions and radiotherapy was administered 
after first surgery. 
 LC3b - Biopsy 1 LC3b - Biopsy 2 LC3b - Biopsy 3 
Case 1 
 
4 4 
 
Case 
2 
 
4 
 
5 
 
Case 
3 
 
5 
 
5 
 
5 
 
Figure 5.6: Representative staining examples and staining scores LC3b in three cases of 
recurrent glioblastoma. 
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Figure 5.7: Representative staining examples and staining scores p62 in three cases of 
recurrent glioblastoma. 
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5:4) Discussion: 
LC3b and p62 analysis was possible in only 45 patients.   Here, LC3B staining was not 
significantly associated with patient survival by either linear regression or Kaplan Meier 
survival analysis.  It is important to note here that the antibody used detects both cellular 
forms of LC3b i.e., LC3b I and LC3b II.  Whilst LC3b I is cytosolic in distribution, LC3b II 
is associated with autophagosome membrane and autophagy induction leads to an increase in 
LC3b II.  This probably explains the diffuse but punctate staining that was observed in our 
study.  The two cellular forms of LC3b can be detected by immunoblotting but a 
commercially available antibody which differentiates between the two forms on 
immunohistochemistry is currently not available.  To date, a study by Aoki et al. (2008) is the 
only previous study to have reported LC3b immunohistochemical analysis in glioblastomas.  
The study involved 65 patients with Glioblastoma and both immunoblotting and 
immunohistochemical analysis of LC3b was performed.  Whilst they reported a significant 
relationship between LC3B and Karnofsky performance scale score, there was no significant 
relationship with survival.  It is important to note here that Aoki et al. did not take into 
account the nuclear staining of LC3b and secondly the cytoplasmic staining was classified as 
weakly positive or strong positive.  In  this thesis, both nuclear and cytoplasmic staining were 
taken into account as nuclear presence of LC3b and LC3b shuttling between nucleoplasm and 
cytoplasm is a well known although poorly understood concept (Drake et al., 2010).  Also, 
the thesis has employed a more quantitative method of analysing the staining, thereby 
reducing the extent of subjectivity in analysis.  The study found no association between 
cytoplasmic staining scores and patient survival.   
Interestingly a positive association between LC3b and p62 staining scores was observed.  
Similar immunohistochemical analysis in glioblastomas has not been reported before.  This 
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observation is in keeping with the study by Shvets et al. (2008) who described how LC3 
recruits p62 into autophagosomes, the role of this interaction requires further investigation.   
A significant negative correlation between p62 staining and patient survival on Kaplan Meier 
survival analysis but not on linear regression was discovered.  To the author’s knowledge, 
this has not previously been reported in glioblastoma.   Similar observations have however 
been made in non-small-cell lung cancer where higher levels of p62 are associated with poor 
prognosis (Inoue et al., 2012).  Also p62 expression increases with increasing grade in breast 
Cancer (Rolland et al., 2007).  The role of p62 in oncogenesis remains a subject of active 
current research (Puissant et al., 2012).   p62 accumulation is not only an indication of 
autophagy blockade but is also associated with an amplification of pre-tumoural signalling 
with its presence at crossroads between multiple pro-oncogenic tumoural pathways (Puissant 
et al., 2012).   
Another interesting observation is the high staining scores of LC3b and p62 observed in giant 
cell glioblastoma.  This has not been reported before and probably contributes to the poor 
prognosis associated with these tumours as compared with the usual glioblastoma (Louis et 
al., 2007).   
Analysis of three cases of recurrent Glioblastoma did not reveal any significant change in the 
staining scores of LC3b or p62.  Although the number of cases is too small to draw definite 
conclusions, this observation suggests that adjuvant treatments including radiotherapy and 
temozolomide, do not affect the autophagy flux in the surviving tumour cells.    
This analysis of immunohistochemical expression of LC3b and p62 suggests that autophagy 
plays an important role in glioblastoma oncogenesis and probably contributes to the high 
degree of resistance that these tumours exhibit towards available treatments.  As described in 
chapter 1, immunohistochemical analysis of LC3b and p62 provides an indication and not the 
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exact state of autophagy flux and our results certainly encourage the need for further research 
in this field in Glioblastoma and other CNS tumours possibly with addition of more methods 
of protein quantification.     
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Chapter 6 
Conclusions and future work 
Improving patient survival remains a challenge in the management of Glioblastoma and in 
spite of advances in neuroradiology, image guided neurosurgery, neuropathology and 
neurooncology, prognosis remains poor.  Age, performance score, gross total surgical 
resecttion, radiotherapy, temozolomide, MGMT status and IDH-1 are well described and 
established prognostic markers in glioblastoma.  Whilst clinical experience and published 
data suggest that most patients with glioblastoma will be dead within fifteen months of 
diagnosis, in spite of maximal treatment, approximately 3-5% will survive much longer and 
seem to respond to the established treatments better than would be predicted (Krex et al., 
2007) with isolated case reports of patient surviving up to 20 years after diagnosis (Sperduto 
et al., 2009).  This clearly points to biological differences which, if identified, would help to 
predict treatment response and drive future research in to targeted therapy.   
The analysis of complex pathways of cellular proliferation, differentiation, apoptosis, stress 
response, survival and DNA damage response are the subject of intense current research with 
an aim of identifying unique molecular signatures and biomarkers of prognostic and 
predictive significance in cancer.  Identification of such markers will enable more focused 
targeting of existing therapies to patients who are likely to respond well to them.  The aim of 
this thesis was to study the expression of a panel of cell division, autophagy and apoptosis 
markers in glioblastoma in an attempt to identify biomarkers prognostic and/or predictive 
significance.  The markers used are readily available and can be applied to routine diagnostic 
immunohistochemistry (IHC) and neuropathology practice. 
This study involved construction of tissue micro-array for IHC analysis of a panel of 
biomarkers.  This not only proved cost effective in terms of antibody use but also allowed 
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standardised IHC staining as all representative glioblastoma tissue samples could be analysed 
on three slides which were processed together. 
This study has its limitations.  Firstly, the sample size was small which prevented the 
application of more advanced statistical analysis.  Secondly, only a single semi-quantitative 
method of protein expression was used.  The results will therefore need further validation by 
the use of another techniques particularly immunoblotting and also real time reverse 
transcription quantitative PCR (polymerase chain reaction) for mRNA expression of the 
studied markers.  Thirdly, none of the patients in the study had charactererization of MGMT 
and IDH-1 which are now known to be important prognostic markers.  This was due to the 
fact that MGMT analysis was not in clinical use at Hull Royal Infirmary at the time of this 
study and IDH-1 was only reported as a prognostic marker in glioblastoma in 2009.  Inspite 
of these limitations, this work has led to some interesting and significant results.    
Whilst IHC expression of cell cycle markers has been studied previously in glioblastoma, a 
marker of prognostic significance has not been reported.  This work has identified two cell 
cycle markers, Cyclin A and Geminin to be of prognostic significance in glioblastoma and 
the results also point to a significant predictive value.   
The study also reconfirms the observation that the effects of adjuvant treatment is cell cycle 
phase specific and seems to target cell populations in S and G2 phase of the cell cycle; 
populations identifiable by cyclin A and geminin expression.  The incorporation of cyclin A 
and Geminin in the neuropathology diagnostic panel would therefore provide neurooncology 
multidisciplinary teams with additional prognostic information that could aid in decision 
making and help to better target currently available adjuvant treatments.  
Apotosis has been a subject of extensive research in cancer in general and glioblastoma in 
particular.  The current study used five common, important, markers of apoptosis and showed 
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a negative correlation between Bak IHC expression and patient survival, in spite of the small 
sample size.  To the author’s knowledge, this correlation has not been reported previously in 
the literature.  This observation however needs further investigation as it suggests a role of 
Bak in glioblastoma oncogenesis beyond its known pro-apoptotic function; such a function 
could have major implications for understanding key biological processes as well as 
prognostic value. 
Autophagy flux and autophagic cell death is an extremely “hot topic” currently in cancer.  
IHC analysis of autophagy flux is difficult and this study is the first to analyse and quantify 
the IHC expression of two markers (LC3b and p62) of autophagy flux in gliblastoma.  A key 
finding was the significant negative correlation between p62 expression and patient survival; 
this clearly points to autophagy flux playing a major role in glioblastoma onncogenesis.  
Whilst a recommendation for routine clinical use of p62 as a prognostic marker cannot be 
made at this stage, the study clearly identifies an area for future research and suggests a 
possible target for interventions.   
Currently glioblastoma oncogenesis and targeted therapy is the subject of ongoing research 
(Westermark, 2012; Ohka et al., 2012).  The Cancer Genome Atlas (TCGA) project 
catalogues genomic abnormalities involved in the development of cancer using wide ranging 
techniques and its analysis has led to a recent description of glioblastoma subclassification in 
to four types based on gene expression, somatic mutations and DNA copy number (Cancer 
Genome Atlas Research Network, 2008; Verhaak et al., 2010).  These subtypes are 
characterized by PDGFRA, IDH1, EGFR and NF1 pathway abnormalities.  This sub-
classification will need to be considered in relation to other studies such as those conducted 
here as a focus on cell cycle and autophagy machinery is relevant as these pathways act as an 
integration point for information transduced through upstream pathways.  The results of this 
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thesis are not only likely to be useful in every day clinical practice and management of 
patients with glioblastoma but they also provide material for further research into cell cycle 
and in particular autophagy machinery in an effort to identify prognostic and predictive 
biomarkers and targets for future therapies.    
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 Table 1:  Group 1 cell cycle markers 
No.  Sex Date of 
Diagnosis 
Survival 
(days) 
Age at 
Diagnosis 
(years) 
Procedure  
1-Debulk, 
2-Bx 
Geminin 
% 
MCM-
2 % 
Cyclin 
A % 
Karnovsky 
Score 
Radiotherapy PCV 
Chemo-
therapy 
Temozolomide 
1 F 20/11/2002 170 53 1 16.15 20.40 7.68 80 Yes No No 
2 F 01/02/2003 144 61 1 4.68 43.73 3.97 70 Yes No No 
3 M 13/02/2003 285 55 1 4.50 27.99 2.72 60 Yes No No 
4 M 02/07/2003 386 58 1 7.34 22.13 4.13 70 Yes No No 
5 M 21/07/2003 150 63 1 6.42 15.56 0.39 70 Yes No No 
6 M 31/07/2003 437 50 1 7.66 30.04 5.02 90 Yes Yes No 
7 F 22/10/2003 173 74 1 6.47 38.18 4.21 60 Yes No No 
8 M 19/11/2003 408 47 1 14.83 23.24 6.56 80 Yes Yes No 
9 M 27/11/2003 401 56 1 10.66 19.99 6.94 90 Yes No No 
10 F 01/12/2003 540 54 1 13.63 68.25 11.81 70 Yes No No 
11 M 02/12/2003 204 59 1 5.18 15.38 0.94 70 Yes No No 
12 F 22/12/2003 143 69 1 5.11 33.78 2.43 60 Yes No No 
13 F 15/01/2004 453 60 2 9.46 26.59 3.58 80 Yes No No 
14 M 04/02/2004 279 63 1 6.47 30.66 6.23 70 Yes No No 
15 M 13/09/2004 336 64 1 5.82 28.40 3.50 60 Yes No No 
16 M 05/10/2004 87 61 1 2.85 15.26 2.41 70 Yes No No 
17 M 24/01/2005 210 43 1 4.26 21.72 3.08 70 Yes No No 
18 F 09/02/2005 169 79 1 3.88 22.90 2.48 50 Yes No No 
19 M 18/05/2005 314 81 2 10.39 40.29 5.09 70 Yes No No 
20 F 19/05/2005 237 58 1 2.93 23.85 1.65 60 Yes No No 
21 M 12/08/2005 388 64 2 10.47 54.86 5.10 60 Yes No No 
22 F 13/09/2006 689 40 1 9.55 73.32 7.55 80 Yes No Yes 
23 M 05/07/2007 165 29 2 5.11 9.45 2.00 60 Yes No Yes 
24 F 15/08/2007 417 66 1 7.79 44.69 2.36 60 Yes No No 
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25 M 28/08/2007 177 69 1 2.88 9.22 0.83 60 Yes No No 
26 F 11/09/2007 325 38 1 9.57 50.83 7.90 60 Yes No Yes 
27 M 04/10/2007 300 64 1 7.80 49.33 4.07 50 Yes No No 
28 M 15/11/2007 270 56 1 13.19 77.98 7.04 60 Yes No No 
29 M 28/11/2007 378 57 1 7.87 54.40 4.51 60 Yes No Yes 
30 F 30/01/2008 145 58 1 8.60 42.03 3.63 60 Yes No Yes 
31 M 03/03/2008 129 61 1 9.26 33.25 6.04 50 Yes No Yes 
32 M 03/03/2008 269 61 1 12.48 47.95 10.13 60 Yes No Yes 
33 M 07/03/2008 180 65 1 13.22 55.52 6.52 60 Yes No Yes 
34 M 25/03/2008 246 65 1 10.71 56.75 7.83 60 Yes No Yes 
35 M 31/03/2008 220 64 1 4.76 40.67 4.08 60 Yes No Yes 
36 M 28/04/2008 104 56 2 6.09 43.59 3.53 60 Yes No Yes 
37 M 30/04/2008 144 61 2 9.25 51.78 6.86 60 Yes No Yes 
38 M 17/06/2008 153 67 2 6.16 57.45 5.06 60 Yes No Yes 
39 M 30/06/2008 111 62 2 6.41 31.14 1.99 50 Yes No Yes 
40 M 02/07/2008 159 69 1 11.53 55.97 3.99 60 Yes No Yes 
41 M 05/08/2008 166 72 1 3.69 21.15 1.96 60 Yes No Yes 
42 M 25/02/2006 1059 19 1 8.70 34.64 7.37 70 Yes Yes No 
43 M 06/08/2007 596 28 1  - 44.59 14.75 80 Yes No Yes 
44 M 07/08/2007 595 46 1 10.29 19.69 4.50 60 Yes No Yes 
45 F 15/02/2008 405 70 1 17.60 74.04 8.76 60 Yes No Yes 
46 F 06/04/2008 355 60 1 15.99 68.09 11.59 70 Yes Yes Yes 
47 F 27/03/2008 365 54 1 9.67 19.27 1.12 60 Yes No Yes 
48 F 24/04/2008 337 36 1 19.67 54.41 4.50 70 Yes No Yes 
49 M 01/09/2008 208 50 1 6.33 29.31 1.98 60 Yes No Yes 
50 F 01/09/2008 208 62 1 6.29 41.21 2.00 60 Yes No Yes 
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Table 2:  Group 2 cell cycle markers 
No. Sex Date of 
Diagnosis 
Survival 
(days) 
Age at 
Diagnosis 
(years) 
Procedure  
1-Debulk, 
2-Bx 
Geminin 
LI % 
MCM-
2 LI  % 
Cyclin 
A LI  
% 
Karnovsky 
Score 
Radio-
therapy 
PCV 
Chemo-
therapy 
Temozolomide 
1 F 29/12/2003 53 70 2 8.60 32.34 6.655 50 No No No 
2 F 13/03/2004 47 50 2 7.61 47.24 5.25 50 No No No 
3 M 25/06/2003 89 73 1 3.43 10.04 0.82 60 No No No 
4 F 13/10/2003 87 62 1 6.08 14.49 2.40 50 No No No 
5 M 27/04/2005 111 64 1 9.38 73.75 9.61 60 No No No 
6 F 04/08/2005 37 75 1 5.86 43.76 4.76 50 No No No 
7 F 13/10/2005 36 75 1 5.86 43.76 4.76 50 No No No 
8 F 13/12/2005 128 77 1 5.40 34.71 3.53 60 No No No 
9 M 31/07/2007 27 74 1 8.88 28.05 4.02 40 No No No 
10 M 09/08/2007 66 63 1 5.82 43.02 5.22 60 No No No 
11 F 07/01/2008 63 73 1 12.50 56.34 8.67 60 No No No 
12 F 29/04/2008 34 51 1 9.25 51.78 6.86 20 No No No 
13 F 27/05/2008 68 70 1 8.76 45.93 4.69 50 No No No 
14 M 24/06/2008 35 52 1 12.76 58.95 4.04 50 No No No 
15 M 18/09/2008 137 63 1 7.65 50.36 6.09 40 No No No 
16 F 21/10/2008 72 61 1 7.64 35.06 1.73 50 No No No 
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Table 3: Markers of apoptosis 
No. Sex Date of 
Diagnosis 
Survival 
(days) 
Age at 
Diagnosis 
(years) 
Procedu
re  1-
Debulk, 
2-Biopsy 
Bcl-2 
LI % 
Bcl-xl 
LI % 
Bak 
LI % 
Caspase
3 LI % 
Karnovsky 
Score 
Radio-
therapy 
PCV 
Chemo-
therapy 
Temozolomide 
1 F 20/11/2002 170 53 1 4.20 2.01 23.22 23.39 80 Yes No No 
2 M 23/01/2003 616 64 1 12.59 1.60 6.91 34.56 70 Yes No No 
3 F 01/02/2003 144 61 1 2.87 1.23 9.41 22.88 70 Yes No No 
4 M 13/02/2003 285 55 1 1.36 3.91 18.81 26.42 60 Yes No No 
5 M 25/06/2003 89 73 1 7.39 5.19 18.89 38.31 60 No No No 
6 M 02/07/2003 386 58 1 11.69 0.76 7.96 43.36 70 Yes No No 
7 M 21/07/2003 150 63 1 8.38 1.37 25.20 48.90 70 Yes No No 
8 M 31/07/2003 437 50 1 1.04 1.39 14.64 52.92 90 Yes Yes No 
9 F 13/10/2003 87 62 1 12.85 1.70 21.35 45.48 50  No No No 
10 M 16/10/2003 384 56 1 3.65 5.06 9.09 64.95 90 Yes No  No 
11 F 22/10/2003 173 74 1 2.43 0.87 19.41 75.26 60 Yes No No 
12 M 19/11/2003 408 47 1 8.30 4.36 6.71 47.69 80 Yes Yes No 
13 M 27/11/2003 401 56 1 22.76 1.98 1.46 14.56 90 Yes No No 
14 F 01/12/2003 540 54 1 9.24 2.40 3.26 59.05 70 Yes No No 
15 M 02/12/2003 204 59 1 7.92 10.19 48.83 72.97 70 Yes No No  
16 F 15/01/2004 453 60 2 10.51 3.58 32.92 69.69 80 Yes No No 
17 M 04/02/2004 279 63 1 13.43 0.84 4.21 17.79 70 Yes No No 
18 F 24/02/2004 282 59 1 0.14 0.53 3.17 90.06 60 Yes No No 
19 M 13/09/2004 336 64 1 21.99 3.71 42.90 50.18 60 Yes No No 
20 M 05/10/2004 87 61 1 10.98 3.54 50.06 73.68 70 Yes No No 
21 M 24/01/2005 210 43 1 0.66 0.86 11.62 31.62 70 Yes No No 
22 F 09/02/2005 169 79 1 14.55 -  24.26 53.63 50 Yes No No 
23 M 27/04/2005 111 64 1 3.28 2.28 50.24 68.40 60 Yes No No 
24 M 18/05/2005 314 81 2 11.87 1.06 5.16 75.85 70 Yes No No 
25 F 19/05/2005 237 58 1 1.55 0.67 10.27 77.39 60 Yes No No 
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26 M 12/08/2005 388 64 2 0.17 0.57 16.13 97.72 60 Yes No No 
27 F 13/10/2005 36 75 1 10.83 - - - 50 No No No 
28 F 13/12/2005 128 77 1 2.15 14.09 31.54 38.02 60 No No No 
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Table 4: Markers of autophagy 
No. Sex Date of 
Diagnosis 
Survival 
(days) 
Age at 
Diagnosis 
(years) 
Procedure  
1-Debulking, 
2-Biopsy 
LC3B 
staining 
score 
p62 
staining 
score 
Karnovsky 
Score 
Radio-
therapy 
PCV 
Chemo-
therapy 
Temozolomide 
1 F 20/11/2002 170 53 1 3 2 80 Yes No No 
 F 01/02/2003 144 61 1 3 3 70 Yes No No 
3 M 13/02/2003 285 55 1 5 4 60 Yes No No 
4 M 02/07/2003 386 58 1 5 3 70 Yes No No 
5 M 21/07/2003 150 63 1 5 4 70 Yes No No 
6 F 22/10/2003 173 74 1 4 3 60 Yes No No 
7 M 19/11/2003 408 47 1 3 3 80 Yes Yes No 
8 M 27/11/2003 401 56 1 3 2 90 Yes No No 
9 F 01/12/2003 540 54 1 4 3 70 Yes No No 
10 M 02/12/2003 204 59 1 3 3 70 Yes No No 
11 F 22/12/2003 143 69 1 4 4 60 Yes No No 
12 F 15/01/2004 453 60 2 3 3 80 Yes No No 
13 M 04/02/2004 279 63 1 4 3 70 Yes No No 
14 M 13/09/2004 336 64 1 5 4 60 Yes No No 
15 M 05/10/2004 87 61 1 5 5 70 Yes No No 
16 M 24/01/2005 210 43 1 4 3 70 Yes No No 
17 F 09/02/2005 169 79 1 5 4 50 Yes No No 
18 M 18/05/2005 314 81 2 5 3 70 Yes No No 
19 F 19/05/2005 237 58 1 3 2 60 Yes No No 
20 M 12/08/2005 388 64 2 3 2 60 Yes No No 
21 F 15/08/2007 417 66 1 4 2 60 Yes No No 
22 M 28/08/2007 177 69 1 4 2 60 Yes No No 
23 F 11/09/2007 325 38 1 4 2 60 Yes No Yes 
24 M 04/10/2007 300 64 1 4 3 50 Yes No No 
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25 M 15/11/2007 270 56 1 5 4 60 Yes No No 
26 M 28/11/2007 378 57 1 5 4 60 Yes No Yes 
27 F 30/01/2008 145 58 1 4 3 60 Yes No Yes 
28 M 03/03/2008 129 61 1 5 3 50 Yes No Yes 
29 M 03/03/2008 269 61 1 5 3 60 Yes No Yes 
30 M 07/03/2008 180 65 1 5 3 60 Yes No Yes 
31 M 25/03/2008 246 65 1 5 3 60 Yes No Yes 
32 M 31/03/2008 220 64 1 5 2 60 Yes No Yes 
33 M 28/04/2008 104 56 2 5  60 Yes No Yes 
34 M 17/06/2008 153 67 2 2 2 60 Yes No Yes 
35 M 30/06/2008 111 62 2 5 2 50 Yes No Yes 
36 M 02/07/2008 159 69 1 5 4 60 Yes No Yes 
37 M 05/08/2008 166 72 1 4 2 60 Yes No Yes 
38 M 25/02/2006 1059 19 1 5 3 70 Yes Yes No 
39 M 06/08/2007 596 28 1 4 2 80 Yes No Yes 
40 M 07/08/2007 595 46 1 4 2 60 Yes No Yes 
41 F 15/02/2008 405 70 1 5 3 60 Yes No Yes 
42 F 06/04/2008 355 60 1 5 3 70 Yes Yes Yes 
43 F 27/03/2008 365 54 1 5 3 60 Yes No Yes 
44 F 24/04/2008 337 36 1 5 2 70 Yes No Yes 
45 M 01/09/2008 208 50 1 4 2 60 Yes No Yes 
 
 
